<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:06:26Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5658516" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:5658516</identifier><datestamp>2017-11-02</datestamp><setSpec>elsevierwt</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Cell Chem Biol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Cell Chem Biol</journal-id>
      <journal-title-group>
        <journal-title>Cell Chemical Biology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2451-9456</issn>
      <issn pub-type="epub">2451-9456</issn>
      <publisher>
        <publisher-name>Cell Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5658516</article-id>
      <article-id pub-id-type="pmcid">PMC5658516</article-id>
      <article-id pub-id-type="pmc-uid">5658516</article-id>
      <article-id pub-id-type="pmid">28919039</article-id>
      <article-id pub-id-type="publisher-id">S2451-9456(17)30280-5</article-id>
      <article-id pub-id-type="doi">10.1016/j.chembiol.2017.08.006</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A Linear Diubiquitin-Based Probe for Efficient and Selective Detection of the Deubiquitinating Enzyme OTULIN</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Weber</surname>
            <given-names>Aurelia</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Elliott</surname>
            <given-names>Paul R.</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pinto-Fernandez</surname>
            <given-names>Adan</given-names>
          </name>
          <xref rid="aff3" ref-type="aff">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bonham</surname>
            <given-names>Sarah</given-names>
          </name>
          <xref rid="aff3" ref-type="aff">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kessler</surname>
            <given-names>Benedikt M.</given-names>
          </name>
          <xref rid="aff3" ref-type="aff">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Komander</surname>
            <given-names>David</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>El Oualid</surname>
            <given-names>Farid</given-names>
          </name>
          <email>farideloualid@ubiqbio.com</email>
          <xref rid="aff4" ref-type="aff">4</xref>
          <xref rid="cor1" ref-type="corresp">â</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Krappmann</surname>
            <given-names>Daniel</given-names>
          </name>
          <email>daniel.krappmann@helmholtz-muenchen.de</email>
          <xref rid="aff1" ref-type="aff">1</xref>
          <xref rid="fn1" ref-type="fn">5</xref>
          <xref rid="cor2" ref-type="corresp">ââ</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Research Unit Cellular Signal Integration, Institute of Molecular Toxicology and Pharmacology, Helmholtz Zentrum MÃ¼nchen - German Research Center for Environmental Health, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany</aff>
      <aff id="aff2"><label>2</label>Medical Research Council Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, UK</aff>
      <aff id="aff3"><label>3</label>Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7FZ, UK</aff>
      <aff id="aff4"><label>4</label>UbiQ Bio BV, Science Park 408, 1098 XH Amsterdam, the Netherlands</aff>
      <author-notes>
        <corresp id="cor1"><label>â</label>Corresponding author <email>farideloualid@ubiqbio.com</email></corresp>
        <corresp id="cor2"><label>ââ</label>Corresponding author <email>daniel.krappmann@helmholtz-muenchen.de</email></corresp>
        <fn id="fn1">
          <label>5</label>
          <p id="ntpara0010">Lead Contact</p>
        </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>19</day>
        <month>10</month>
        <year>2017</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.-->
      <pub-date pub-type="ppub">
        <day>19</day>
        <month>10</month>
        <year>2017</year>
      </pub-date>
      <volume>24</volume>
      <issue>10</issue>
      <fpage>1299</fpage>
      <lpage>1313.e7</lpage>
      <history>
        <date date-type="received">
          <day>17</day>
          <month>2</month>
          <year>2017</year>
        </date>
        <date date-type="rev-recd">
          <day>10</day>
          <month>7</month>
          <year>2017</year>
        </date>
        <date date-type="accepted">
          <day>1</day>
          <month>8</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© 2017 MRC Laboratory of Molecular Biology</copyright-statement>
        <copyright-year>2017</copyright-year>
        <license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p>
        </license>
      </permissions>
      <abstract id="abs0010">
        <title>Summary</title>
        <p>The methionine 1 (M1)-specific deubiquitinase (DUB) OTULIN acts as a negative regulator of nuclear factor ÎºB signaling and immune homeostasis. By replacing Gly76 in distal ubiquitin (Ub) by dehydroalanine we designed the diubiquitin (diUb) activity-based probe Ub<sub>G76Dha</sub>-Ub (OTULIN activity-based probe [ABP]) that couples to the catalytic site of OTULIN and thereby captures OTULIN in its active conformation. The OTULIN ABP displays high selectivity for OTULIN and does not label other M1-cleaving DUBs, including CYLD. The only detectable cross-reactivities were the labeling of USP5 (Isopeptidase T) and an ATP-dependent assembly of polyOTULIN ABP chains via Ub-activating E1 enzymes. Both cross-reactivities were abolished by the removal ofÂ the C-terminal Gly in the ABP's proximal Ub, yielding the specific OTULIN probe Ub<sub>G76Dha</sub>-Ub<sub>ÎG76</sub> (OTULIN ABPÎG76). Pull-downs demonstrate that substrate-bound OTULIN associates with the linear ubiquitin chain assembly complex (LUBAC). Thus, we present a highly selective ABP for OTULIN that will facilitate studying the cellular function of this essential DUB.</p>
      </abstract>
      <abstract abstract-type="graphical" id="abs0015">
        <title>Graphical Abstract</title>
        <fig id="undfig1" position="anchor">
          <graphic xlink:href="fx1"/>
        </fig>
      </abstract>
      <abstract abstract-type="author-highlights" id="abs0020">
        <title>Highlights</title>
        <p>
          <list list-type="simple">
            <list-item id="u0010">
              <label>â¢</label>
              <p>Chemical synthesis of the OTULIN ABPs Ub<sub>G76Dha</sub>-Ub and Ub<sub>G76Dha</sub>-Ub<sub>ÎG76</sub></p>
            </list-item>
            <list-item id="u0015">
              <label>â¢</label>
              <p>OTULIN ABPs display high selectivity for labeling OTULIN</p>
            </list-item>
            <list-item id="u0020">
              <label>â¢</label>
              <p>Chemical tool to monitor OTULIN activity and interactions in cells</p>
            </list-item>
            <list-item id="u0025">
              <label>â¢</label>
              <p>Substrate-bound OTULIN associates with cellular LUBAC</p>
            </list-item>
          </list>
        </p>
      </abstract>
      <abstract abstract-type="teaser" id="abs0025">
        <p>Weber etÂ al. report on the chemical synthesis of highly selective OTULIN activity-based probes (ABPs) useful for studying enzymatic activity and cellular functions of the M1-linkage-specific ubiquitin hydrolase OTULIN.</p>
      </abstract>
      <kwd-group id="kwrds0010">
        <title>Keywords</title>
        <kwd>OTULIN</kwd>
        <kwd>DUB</kwd>
        <kwd>HOIP</kwd>
        <kwd>activity-based probe</kwd>
        <kwd>M1-linked</kwd>
        <kwd>ubiquitin chains</kwd>
        <kwd>ubiquitin-activating E1</kwd>
      </kwd-group>
    </article-meta>
    <notes>
      <p id="misc0010">Published: September 14, 2017</p>
    </notes>
  </front>
  <body>
    <sec id="sec1">
      <title>Introduction</title>
      <p>By assembling covalent chains with distinct linkages, the post-translational modifier ubiquitin (Ub) controls nearly all aspects of cell biology and cellular homeostasis (<xref rid="bib29" ref-type="bibr">Komander and Rape, 2012</xref>). Conjugation of methionine 1 (M1)-linked polyubiquitin (polyUb) is catalyzed by the linear ubiquitin chain assembly complex (LUBAC), consisting of HOIP/RNF31, HOIL-1, and SHARPIN (<xref rid="bib19" ref-type="bibr">Fiil and Gyrd-Hansen, 2014</xref>, <xref rid="bib25" ref-type="bibr">Iwai etÂ al., 2014</xref>). Upon stimulation, LUBAC is recruited to immune receptors, e.g., tumor necrosis factor receptor (TNFR), interleukin-1 receptor, and Toll-like receptors, where it decorates signaling mediators such as RIPKs, MYD88, IRAKs, and NEMO with M1-linked Ub chains to facilitate nuclear factor ÎºB (NF-ÎºB)-dependent immune and inflammatory responses. In turn, LUBAC activity needs to be tightly controlled and the deubiquitinases (DUBs) CYLD and OTULIN cleave M1-linked polyUb with high specificity and efficiency (<xref rid="bib26" ref-type="bibr">Keusekotten etÂ al., 2013</xref>, <xref rid="bib30" ref-type="bibr">Komander etÂ al., 2009b</xref>, <xref rid="bib44" ref-type="bibr">Rivkin etÂ al., 2013</xref>). Indeed, OTULIN and CYLD bind to LUBAC via a PUB (peptide:N-glycanase/UBA- or UBX-containing proteins) domain in HOIP. While OTULIN binds HOIP directly through its PUB-interacting motif (PIM) (<xref rid="bib14" ref-type="bibr">Elliott etÂ al., 2014</xref>, <xref rid="bib47" ref-type="bibr">Schaeffer etÂ al., 2014</xref>), CYLD is recruited via a PIM in the bridging factor SPATA2 (<xref rid="bib13" ref-type="bibr">Elliott etÂ al., 2016</xref>, <xref rid="bib32" ref-type="bibr">Kupka etÂ al., 2016</xref>, <xref rid="bib50" ref-type="bibr">Schlicher etÂ al., 2016</xref>, <xref rid="bib55" ref-type="bibr">Wagner etÂ al., 2016</xref>). PUB-PIM interactions with HOIP are mutually exclusive, and while OTULIN-LUBAC and CYLD/SPATA2-LUBAC complexes are readily detectable, only CYLD/SPATA2-LUBAC is efficiently recruited to TNFR complexes after TNF stimulation (<xref rid="bib13" ref-type="bibr">Elliott etÂ al., 2016</xref>, <xref rid="bib32" ref-type="bibr">Kupka etÂ al., 2016</xref>, <xref rid="bib50" ref-type="bibr">Schlicher etÂ al., 2016</xref>, <xref rid="bib55" ref-type="bibr">Wagner etÂ al., 2016</xref>). Nevertheless, OTULIN is also a negative regulator of TNF-Î± signaling (<xref rid="bib6" ref-type="bibr">Damgaard etÂ al., 2016</xref>, <xref rid="bib22" ref-type="bibr">Hrdinka etÂ al., 2016</xref>, <xref rid="bib26" ref-type="bibr">Keusekotten etÂ al., 2013</xref>). Furthermore, it serves to prevent auto-ubiquitination of LUBAC components at steady state, and accumulation of M1-linked chains in general (<xref rid="bib14" ref-type="bibr">Elliott etÂ al., 2014</xref>, <xref rid="bib18" ref-type="bibr">Fiil etÂ al., 2013</xref>, <xref rid="bib26" ref-type="bibr">Keusekotten etÂ al., 2013</xref>, <xref rid="bib47" ref-type="bibr">Schaeffer etÂ al., 2014</xref>). Genetically, an OTULIN loss-of-function mouse model displayed developmental defects in angiogenesis, leading to embryonic lethality (<xref rid="bib44" ref-type="bibr">Rivkin etÂ al., 2013</xref>). Conditional knockout (KO) mice with OTULIN deletion in immune cells demonstrated that OTULIN is critical for preventing spontaneous inflammation and maintaining immune homeostasis (<xref rid="bib6" ref-type="bibr">Damgaard etÂ al., 2016</xref>). This correlated with hypomorphic mutations in human patients and led to the description of an OTULIN-related auto-inflammatory syndrome (<xref rid="bib6" ref-type="bibr">Damgaard etÂ al., 2016</xref>, <xref rid="bib59" ref-type="bibr">Zhou etÂ al., 2016</xref>). Despite its pathophysiological importance, questions remain regarding whether and how the DUB activity and LUBAC interaction of OTULIN are regulated in cells.</p>
      <p>Activity-based probes (ABPs) are powerful tools to study enzyme activities <italic>inÂ vitro</italic> and <italic>inÂ vivo</italic> and have been helpful for studying the activity of DUBs (<xref rid="bib10" ref-type="bibr">Ekkebus etÂ al., 2014</xref>). Whereas many DUBs react with ABPs containing an electrophilic group at the C terminus of a monoUb (<xref rid="bib7" ref-type="bibr">de Jong etÂ al., 2012</xref>), the substrate-assisted Ub chain hydrolysis of OTULIN relies on a native M1-linked diubiquitin (diUb) as a substrate (<xref rid="bib26" ref-type="bibr">Keusekotten etÂ al., 2013</xref>, <xref rid="bib36" ref-type="bibr">Mevissen etÂ al., 2013</xref>). The design of an electrophile that mimics the Gly-Met environment of the linear diUb linkage has remained a challenge to date. <xref rid="bib35" ref-type="bibr">McGouran etÂ al. (2013)</xref> designed an ABP based on an M1-linked diUb which more promiscuously labeled ubiquitin-specific protease (USP) DUBs that normally show little reactivity for linear Ub chains. OTULIN, however, was not labeled with this probe. The outcome was attributed to the greater flexibility of the used electrophile and the loss of key residues such as the M1 side chain and the amide bond between M1 and Gln2 of the proximal Ub (<xref rid="bib26" ref-type="bibr">Keusekotten etÂ al., 2013</xref>, <xref rid="bib35" ref-type="bibr">McGouran etÂ al., 2013</xref>). <xref rid="bib38" ref-type="bibr">Mulder etÂ al. (2014)</xref> reported the use of a chemical ligation handle that allowed the generation of linkage-specific diUb ABPs based on all seven lysine- and thus isopeptide-linked diUb chains (i.e., K6, K11, K27, K29, K33, K48, and K63). Whereas the design of the electrophile was well-suited to mimic the isopeptide bond between two Ub proteins, the differences in chemistry imposed by the âlinearâ peptide linkage made this strategy impractical for the M1-linked chain type. In another attempt to create an ABP based on linear diUb, M1 of proximal Ub was replaced by the electrophilic dehydroalanine (Dha) residue (<xref rid="bib2" ref-type="bibr">Bernardes etÂ al., 2008</xref>, <xref rid="bib20" ref-type="bibr">Haj-Yahya etÂ al., 2014</xref>). However, the probe was cleaved by OTULIN and USP2 rather than reacting covalently with the active site cysteine residues.</p>
      <p>We report here on the total chemical synthesis of biotinylated linear diUb in which Gly76 of the distal Ub is replaced by Dha (bio-Ub<sub>G76Dha</sub>-Ub: OTULIN ABP) to yield an ABP that covalently labels active OTULIN. By crystallizing the OTULIN-(Ub<sub>G76Dha</sub>-Ub) complex, we show that the probe captures OTULIN in its active state. Proteome-wide mass spectrometry (MS) experiments reveal that the OTULIN ABP cross-reacts only with USP5 (Isopeptidase T) and the Ub-activating E1 enzymes UBA1 and UBA6. Deletion of the C-terminal glycine in the proximal Ub moiety in Ub<sub>G76Dha</sub>-Ub<sub>ÎG76</sub> abolishes USP5 labeling and E1 association, yielding a specific probe for OTULIN (OTULIN ABPÎG76). We show that the probes can be used to monitor cellular OTULIN activity, pull-down (PD) active OTULIN, and co-precipitate the OTULIN-associated E3 ligase LUBAC from cells.</p>
    </sec>
    <sec id="sec2">
      <title>Results</title>
      <sec id="sec2.1">
        <title>Synthesis of Bio-Ub<sub>G76Dha</sub>-Ub (OTULIN ABP)</title>
        <p>Our strategy of generating a biotinylated Ub<sub>G76Dha</sub>-Ub probe (<xref rid="fig1" ref-type="fig">FigureÂ 1</xref>) is based on the earlier reported concept of using a 2-aminothiol residue (in this case Cys) to ligate a proximal and distal Ub part followed by its oxidative elimination to form an electrophilic residue (in our case Dha) (<xref rid="bib38" ref-type="bibr">Mulder etÂ al., 2014</xref>). Using the previously reported linear Fmoc-based solid-phase peptide synthesis of the Ub polypeptide (<xref rid="bib12" ref-type="bibr">El Oualid etÂ al., 2010</xref>), we synthesized biotin-labeled Ub(1â75) (<bold>1a</bold>). Here an aminohexanoic acid linker was introduced to create extra space between the biotin label and N terminus of Ub, allowing efficient access of biotin-binding entities (<xref rid="bib7" ref-type="bibr">de Jong etÂ al., 2012</xref>). The biotin-labeled Ub(1â75) was selectively cleaved from the 2-chlorotrityl resin using 20% 1,1,1,3,3,3-hexafluoroisopropanol in DCM, allowing for pyBOP-mediated coupling of methyl 3-mercaptopropionate at the C terminus. Global deprotection with 90% trifluoroacetic acid and purification by high-performance liquid chromatography (HPLC) gave the desired biotin-labeled Ub(1â75) thioester (<bold>2a</bold>) in 42% overall yield on a 40Â Î¼mol scale. Next, Cys-Ub (<bold>2b</bold>), representing the proximal part of our diUb probe design, was synthesized in a similar fashion and displayed good overall yield of 20% on a 25Â Î¼mol scale. Native chemical ligation of <bold>2a</bold> (30Â mg/mL) and <bold>2b</bold> (26Â mg/mL) was performed in 6Â M Gdn-HCl, 0.15Â M sodium phosphate, pH 7.4, with mercaptophenylacetic acid (MPAA, 100Â mM) as ligation catalyst (<xref rid="bib12" ref-type="bibr">El Oualid etÂ al., 2010</xref>). Liquid chromatography-mass spectrometry (LC-MS) analysis showed that overnight incubation at 37Â°C resulted in full consumption of the proximal Ub mutant <bold>2b</bold> and formation of the ligation product as MPAA disulfide. A short treatment with Tris(2-carboxyethy1)phosphine followed by preparative HPLC gave the diUb conjugate (<bold>3</bold>) in 57% yield. Finally, the Cys residue was completely transformed into the electrophilic Dha, by treating a 2Â mg/mL solution of <bold>3</bold> (30Â mg) in 100Â mM sodium phosphate, pH 8, overnight at 37Â°C with 15 eq of <italic>O</italic>-mesitylenesulfonylhydroxylamine (MSH). The desired probe bio-Ub<sub>G76Dha</sub>-Ub (OTULIN ABP) (<xref rid="fig1" ref-type="fig">FigureÂ 1</xref>) was isolated in 71% yield (21Â mg, 1.2Â Î¼mol) after HPLC purification (<xref rid="mmc1" ref-type="supplementary-material">FigureÂ S1</xref>).<fig id="fig1"><label>FigureÂ 1</label><caption><p>Total Chemical Synthesis of Bio-Ub<sub>G76Dha</sub>-Ub</p><p>The synthesis is described in detail in the main text. See also <xref rid="mmc1" ref-type="supplementary-material">FigureÂ S1</xref>.</p></caption><graphic xlink:href="gr1"/></fig></p>
      </sec>
      <sec id="sec2.2">
        <title>OTULIN ABP Covalently Attaches to the Active Site of OTULIN</title>
        <p>We incubated bio-Ub<sub>G76Dha</sub>-Ub with the catalytic domain of OTULIN (OTULIN<sub>cat</sub>, residues 80â352), which is sufficient for specific binding and cleavage of M1-linked Ub chains by OTULIN (<xref rid="bib26" ref-type="bibr">Keusekotten etÂ al., 2013</xref>). The probe was covalently attached to OTULIN<sub>cat</sub> as evident from a molecular-weight shift in an SDS-PAGE that corresponds to the expected 17Â kDa shiftÂ in migration (<xref rid="fig2" ref-type="fig">FigureÂ 2</xref>A). The probe labeled only active OTULIN, because C129A substitution in the catalytic center completely abolished covalent attachment of the probe. Thus, bio-Ub<sub>G76Dha</sub>-Ub represents the first ABP that couples to the active site of OTULIN (OTULIN ABP). In addition, a point mutation in the S1â² site of OTULIN, W96A, previously shown to severely reduce affinity for M1-linked diUb (<xref rid="bib26" ref-type="bibr">Keusekotten etÂ al., 2013</xref>), also abrogated the assembly of the OTULIN<sub>cat</sub>-diUb product (<xref rid="fig2" ref-type="fig">FigureÂ 2</xref>A). To analyze kinetics of the reaction between the OTULIN ABP and OTULIN, both proteins were incubated at 30Â°C and equimolar concentrations. The OTULIN<sub>cat</sub>-diUb product was visible within 10â60 s, but we did not observe full conversion into the product within 30Â min (<xref rid="fig2" ref-type="fig">FigureÂ 2</xref>B). An approximately 5-fold molar excess of OTULIN ABP was necessary for an almost complete coupling of recombinant OTULIN<sub>cat</sub> within 15Â min (<xref rid="fig2" ref-type="fig">FigureÂ 2</xref>C). As expected for a covalent modifier, the irreversibly reacting ABP efficiently inhibited cleavage of linear tetraUb chains by OTULIN<sub>cat</sub> in a dose-dependent manner (<xref rid="fig2" ref-type="fig">FigureÂ 2</xref>D). Under these <italic>inÂ vitro</italic> conditions, OTULIN ABP prevented cleavage at concentrations between 12 and 37Â nM. To confirm that OTULIN activity is needed for coupling to OTULIN ABP, we used the DUB inhibitor PR-619, which besides OTULIN also inhibits a wide range of DUBs, just as de-neddylating and de-sumoylating enzymes (<xref rid="bib1" ref-type="bibr">Altun etÂ al., 2011</xref>, <xref rid="bib4" ref-type="bibr">Chen etÂ al., 2014</xref>). Indeed, PR-619 blocked cleavage of M1-linked tetraUb chains by OTULIN, as well as the formation of the OTULIN-diUb product, in a dose-dependent manner and at similar concentrations (<xref rid="fig2" ref-type="fig">FigureÂ 2</xref>E). These data demonstrate that the OTULIN ABP efficiently labels the active site of recombinant OTULIN<sub>cat</sub>.<fig id="fig2"><label>FigureÂ 2</label><caption><p>Recombinant OTULIN Is Labeled by the OTULIN ABP</p><p>(A) Recombinant OTULIN<sub>cat</sub> (1Â Î¼g) was incubated with 4Â Î¼g bio-Ub<sub>G76Dha</sub>-Ub (2Â hr, 37Â°C). OTULIN-diUb complex formation was analyzed by Coomassie staining.</p><p>(B) OTULIN<sub>cat</sub> (250Â ng) was incubated at 30Â°C in a 1:1 molar ratio with OTULIN ABP. OTULIN-diUb complex formation was monitored by Silver staining.</p><p>(C) OTULIN<sub>cat</sub> (250Â ng) was incubated with increasing OTULIN ABP concentrations (15Â min, 30Â°C). OTULIN-diUb complex formation was monitored by Silver staining.</p><p>(D) TetraUb cleavage assay was performed after pre-treatment of OTULIN with increasing ABP concentrations. TetraUb chain cleavage was visualized by western blot.</p><p>(E) Left: TetraUb cleavage assay was performed as in (D) in the presence of increasing PR-619 concentrations. Right: OTULIN<sub>cat</sub> (500Â ng) was pre-treated with PR-619 before incubation with 2Â Î¼g OTULIN ABP (5Â min, 30Â°C). OTULIN-diUb complex formation was analyzed by Silver staining.</p></caption><graphic xlink:href="gr2"/></fig></p>
        <p>To verify that the ABP is able to capture OTULIN through its catalytic cysteine, we crystallized the OTULIN-bio-Ub<sub>G76Dha</sub>-Ub complex. The structure was determined from crystals grown inÂ similar conditions as the earlier reported OTULIN C129A-M1diUb complex (<xref rid="bib26" ref-type="bibr">Keusekotten etÂ al., 2013</xref>) and belonged to the same space group with near identical cell dimensions (<xref rid="mmc1" ref-type="supplementary-material">Table S1</xref>) and low root-mean-square deviation (0.51Â Ã for OTULIN catalytic domain and 0.55Â Ã for diUb) (<xref rid="fig3" ref-type="fig">Figures 3</xref>A and 3B). Although the resolution of the OTULIN-bio-Ub<sub>G76Dha</sub>-Ub complex was lower than the non-covalent OTULIN C129A-M1diUb structure (3.0 versus 1.9Â Ã, respectively), the electron density in the well-ordered active site enabled complete building of the thioether bond formed by the reaction between the Dha and C129 of OTULIN (<xref rid="fig3" ref-type="fig">FigureÂ 3</xref>C). The obtained structure deviates only minimally from the previous non-covalent complex structure (PDB: <ext-link ext-link-type="uri" xlink:href="pdb:3ZNZ" id="intref0010">3ZNZ</ext-link>; <xref rid="bib26" ref-type="bibr">Keusekotten etÂ al., 2013</xref>): the position and interactions of the distal and proximal Ub molecules are identical, and the mechanism of Ub-assisted catalysis provided by the proximal Ub molecule in the M1-linked chain, enabled the probe to react with the activated Cys.<fig id="fig3"><label>FigureÂ 3</label><caption><p>Structural Analysis of the OTULIN-bio-Ub<sub>G76Dha</sub>-Ub Complex</p><p>(A) Structure of the covalent OTULIN<sub>cat</sub>-bio-Ub<sub>G76Dha</sub>-Ub complex. OTULIN (amino acids [aa] 80â352) shown in blue with the distal and proximal ubiquitin moieties of OTULIN ABP colored in dark and light green, respectively. Circle: site of the OTULIN catalytic triad. See also <xref rid="mmc1" ref-type="supplementary-material">Table S1</xref>.</p><p>(B) Superimposition of the OTULIN catalytic domains from the OTULIN-bio-Ub<sub>G76Dha</sub>-Ub structure (dark blue) with the OTULIN C129A M1-linked diUb complex (OTULIN C129A; light blue) (PDB: <ext-link ext-link-type="uri" xlink:href="pdb:3ZNZ" id="intref0175">3ZNZ</ext-link>). The diUb moieties are shown as ribbon to highlight the near identical arrangement.</p><p>(C) Close-up views of the OTULIN-bio-Ub<sub>G76Dha</sub>-Ub active site (left) and the OTULIN C129A M1-diUb complex active site (middle). Residues 118â128 are shown as ribbons. Catalytic residues are shown in stick format, as is the Glu16prox residue. The Dha group is shown additionally as spheres. A simulated annealing composite omit map, contoured at 1.2Ï is shown encompassing the key catalytic residues and the Dha group. Right: superimposition of the two structures highlighting the identical arrangement of the catalytic triad.</p></caption><graphic xlink:href="gr3"/></fig></p>
      </sec>
      <sec id="sec2.3">
        <title>OTULIN ABP Selectively Labels the DUBs OTULIN and USP5</title>
        <p>To evaluate the selectivity of OTULIN ABP for OTULIN, we first tested its reactivity <italic>inÂ vitro</italic> against a panel of DUBs from the OTU (ovarian tumor), USP, and UCH (ubiquitin C-terminal hydrolases) families (<xref rid="bib27" ref-type="bibr">Komander etÂ al., 2009a</xref>). Whereas OTULIN ABP could quantitatively label OTULIN, we did not observe any reactivity with the K48-selective DUBs, A20 and OTUB1, which is putatively the closest homolog within the OTU family (<xref rid="fig4" ref-type="fig">FigureÂ 4</xref>A) (<xref rid="bib36" ref-type="bibr">Mevissen etÂ al., 2013</xref>). Neither UCHL1 nor UCHL3 were modified by the ABP, which is in line with structural constraints that do not allow efficient cleavage of Ub polymers (<xref rid="bib27" ref-type="bibr">Komander etÂ al., 2009a</xref>). Also, several USPs (USP2, USP7, and USP8) did not react with the probe, although cleavage by many USPs is not restricted to Ub chain topology. Only a fraction of USP5 (Isopeptidase T) reacted with the OTULIN ABP. Since OTULIN and USP5 are able to cleave M1-linked polyUb, we also tested <italic>inÂ vitro</italic> reactivity with the other M1-hydrolyzing DUBs USP2, USP21, and CYLD (<xref rid="bib30" ref-type="bibr">Komander etÂ al., 2009b</xref>, <xref rid="bib58" ref-type="bibr">Ye etÂ al., 2011</xref>). However, OTULIN ABP did not react with these USP DUBs, revealing that, among M1-hydrolyzing DUBs, the probe displays a high selectivity for OTULIN (<xref rid="fig4" ref-type="fig">Figures 4</xref>A and 4B). All DUBs were active, which was verified either by coupling to the monoUb-based ABP ubiquitin-propargylamide (Ub-PA) (<xref rid="bib11" ref-type="bibr">Ekkebus etÂ al., 2013</xref>) or by cleavage of K48-linked diUb (<xref rid="mmc1" ref-type="supplementary-material">Figures S2</xref>A and S2B). Given the M1- and K63-selective cleavage of CYLD, the lacking coupling to OTULIN ABP was unexpected. Thus, we directly compared labeling of OTULIN and CYLD (583â956) with OTULIN ABP and Ub-PA at equimolar concentrations and again found no coupling of OTULIN ABP to CYLD (<xref rid="mmc1" ref-type="supplementary-material">FigureÂ S2</xref>C). Indeed, when comparing the structures ofÂ OTULIN-Ub<sub>G76Dha</sub>-Ub and non-covalent zebrafish CYLD (C596S) Met1-diUb complexes (<xref rid="bib46" ref-type="bibr">Sato etÂ al., 2015</xref>), it becomes clear that CYLD has a narrow channel that binds the distal Ub tail (<xref rid="fig4" ref-type="fig">Figures 4</xref>C and 4D). There is limited space in the CYLD active site around the Gly76-Met1 peptide bond, as CYLD Asp794, Lys756, and Ser800 form a tight channel. Most likely, this prevents OTULIN ABP from reaching the catalytic Cys in CYLD.<fig id="fig4"><label>FigureÂ 4</label><caption><p>OTULIN ABP Shows Minimal Cross-Reactivity with Other Recombinant DUBs</p><p>(A and B) DUBs (0.5â1Â Î¼M) were incubated with 3Â Î¼M OTULIN ABP (1Â hr, 30Â°C). Labeling was analyzed by Silver staining. Asterisks: DUB-diUb adducts. See also <xref rid="mmc1" ref-type="supplementary-material">Figures S2</xref>A and S2B.</p><p>(C) Close-up of the structure of the catalytic site of OTULIN<sub>cat</sub> (aa 80â352; white surface) reacted to the bio-Ub<sub>G76Dha</sub>-Ub probe (green cartoon). Insert, OTULIN residues that form the substrate channel are shown in stick representation.</p><p>(D) Close-up of structure of the catalytic site of zebrafish CYLD (zCYLD) (aa 578â951, C598S; white surface) bound to Met1-linked diUb (green cartoon) (PDB: <ext-link ext-link-type="uri" xlink:href="pdb:3WXE" id="intref0180">3WXE</ext-link>). Insert, residues from CYLD that form a tight substrate channel around the Gly76-Met1 peptide bond are shown in stick representation.</p><p>(E) Recombinant OTULIN<sub>cat</sub>, USP21<sub>cat</sub>, or CYLD (1Â Î¼g) were incubated with either M1-linked diUb WT or Ub<sub>G76A</sub>-Ub (1Â hr, 37Â°C). diUb cleavage was analyzed by western blot.</p><p>(F) ST-OTULIN<sub>cat</sub> (WT or C129A) was pulled down with Strep-Tactin beads in the presence of M1-linked diUb or Ub<sub>G76A</sub>-Ub. Interaction between diUb and OTULIN<sub>cat</sub> proteins was analyzed by western blot.</p></caption><graphic xlink:href="gr4"/></fig></p>
        <p>Interestingly, the G76Dha substitution in the distal Ub of the probe did not prevent covalent binding to OTULIN, despite the fact that G76S substitution in an M1-linked tetraUb chain abolished recognition and cleavage by OTULIN (<xref rid="bib26" ref-type="bibr">Keusekotten etÂ al., 2013</xref>). Also, it has been reported that the USP domain-containing DUB CYLD requires Gly76 in the distal Ub for proper substrate recognition and cleavage (<xref rid="bib28" ref-type="bibr">Komander etÂ al., 2008</xref>, <xref rid="bib46" ref-type="bibr">Sato etÂ al., 2015</xref>). In line with our probe design, we wanted to determine whether the G76A substitution in diUb (Ub(1â75)-Ala-Ub: Ub<sub>G76A</sub>-Ub) would be tolerated. OTULIN, USP21, and CYLD were unable to cleave the G76A mutant of M1-linked diUb (<xref rid="fig4" ref-type="fig">FigureÂ 4</xref>E). Next, we tested the involvement of the distal Ub G76A in OTULIN binding. For this, we performed PDs of recombinant Strep-tag II-tagged OTULIN<sub>cat</sub>-(ST) together with either linear diUb or Ub<sub>G76A</sub>-Ub (<xref rid="fig4" ref-type="fig">FigureÂ 4</xref>F). As expected, linear diUb was cleaved by wild-type (WT) OTULIN<sub>cat</sub>, and pulled down by the catalytically inactive OTULIN<sub>cat</sub> C129A mutant. In contrast, Ub<sub>G76A</sub>-Ub was not cleaved by OTULIN<sub>cat</sub>(-ST), and also binding to OTULIN WT or OTULIN C129A was severely diminished (<xref rid="fig4" ref-type="fig">FigureÂ 4</xref>F). Thus, Gly76 in the distal Ub contributes to the non-covalent association of OTULIN to M1-linked diUb. However, there is still sufficient binding to enable a covalent reaction of OTULIN with the Dha electrophile in our probe.</p>
      </sec>
      <sec id="sec2.4">
        <title>OTULIN ABP Selectively Labels OTULIN and USP5 in Cell Extracts</title>
        <p>Next, we examined if the OTULIN ABP could also react with OTULIN in cell lysates. We expressed Flag-OTULIN WT and C129A in HEK293 cells and incubated the cell lysates after extraction directly with the probe. OTULIN WT but not the C129A mutant was quantitatively labeled by the probe, as demonstrated by western blot analysis with anti-Flag antibody (<xref rid="fig5" ref-type="fig">FigureÂ 5</xref>A). Further probing with an OTULIN antibody indicated that endogenous OTULIN also completely reacted with the probe. Again, we confirmed the specificity toward OTULIN by monitoring cross-reactivity with several DUBs after overexpression and at endogenous levels (<xref rid="mmc1" ref-type="supplementary-material">Figures S3</xref>A and <xref rid="fig5" ref-type="fig">5</xref>B). We tested OTUB1, YOD1, A20 (all OTU domain), CYLD and USP5 (USP domain), and UCHL3 (UCH domain). With the exception of USP5, which was partially labeled by the OTULIN ABP, none of the other DUBs reacted with the probe. We also determined efficacy of the OTULIN ABP reaction with cellular OTULIN and USP5 in titration and kinetic experiments (<xref rid="fig5" ref-type="fig">Figures 5</xref>C and 5D). At room temperature, 1Â Î¼g of OTULIN ABP was quantitatively labeling endogenous OTULIN in extracts from 2Â Ã 10<sup>7</sup> Jurkat TÂ cells within 15Â min. Similar to the <italic>inÂ vitro</italic> experiments (<xref rid="fig2" ref-type="fig">FigureÂ 2</xref>), an excess of OTULIN ABP is required for efficient labeling, but the slower and partial reactivity with USP5 underscores the high preference of the probe for coupling to OTULIN. Thus, the data provide evidence that, within the analyzed panel of DUBs, the OTULIN ABP labels OTULIN with high selectivity and only partially cross-reacts with USP5.<fig id="fig5"><label>FigureÂ 5</label><caption><p>In Cell Extracts, OTULIN ABP Labels OTULIN and USP5, and Induces PolyUb Chain Formation</p><p>(A) Extracts of Flag-OTULIN WT or C129A overexpressing HEK293 cells (â¼2.5Â Ã 10<sup>5</sup> cells/reaction) were incubated with 1Â Î¼g OTULIN ABP (30Â min, 30Â°C). Labeling of exo- and endogenous OTULIN was analyzed by western blot.</p><p>(B) Cross-reactivity of OTULIN ABP with endogenous DUBs. Incubation of OTULIN ABP in HEK293 extracts was performed as in (A). See also <xref rid="mmc1" ref-type="supplementary-material">FigureÂ S3</xref>A.</p><p>(C and D) Extracts of Jurkat TÂ cells (2Â Ã 10<sup>7</sup> cells) were incubated at room temperature with increasing OTULIN ABP amounts for 15Â min (C) or with 1Â Î¼g OTULIN ABP for different times (D).</p><p>(E) For ATP depletion, extracts from 6Â Ã 10<sup>5</sup> HEK293 cells were incubated with apyrase prior to the incubation with 1Â Î¼g OTULIN ABP for 30Â min. Ubiquitin chain formation and ABP adducts were analyzed by western blot. See also <xref rid="mmc1" ref-type="supplementary-material">FigureÂ S3</xref>B.</p></caption><graphic xlink:href="gr5"/></fig></p>
        <p>To obtain a better picture of the selectivity of the OTULIN ABP, we incubated extracts of HEK293 cells with OTULIN ABP and performed western blots with a specific anti-M1-polyUb antibody that also reacts with the linear diUb-based probe and thus recognizes labeled proteins. Indeed, the OTULIN-diUb product was clearly detectable with the anti-M1-polyUb antibody, but prolonged incubation times for 30Â min at 30Â°C in the extracts led to the appearance of a high-molecular-weight smear that was reminiscent to M1-linked polyUb chains (<xref rid="mmc1" ref-type="supplementary-material">FigureÂ S3</xref>B). We depleted ATP from the extracts by apyrase treatment. Clearly, the <italic>inÂ vitro</italic> polyubiquitination that was detected with anti-M1-polyUb and anti-Ub antibodies relies on an active ATP-dependent process, suggesting that assembly of polyUb smear results from an enzymatic ubiquitination reaction (<xref rid="fig5" ref-type="fig">FigureÂ 5</xref>E). Two prominent bands were detected by the anti-M1-polyUb antibody at â¼60 and â¼130Â kDa upon OTULIN ABP incubation, and anti-OTULIN and anti-USP5 antibodies confirmed that these bands correspond in migration to the OTULIN-diUb and USP5-diUb products (<xref rid="fig5" ref-type="fig">FigureÂ 5</xref>E). Importantly, despite some weaker background signals, OTULIN and USP5Â were the major OTULIN ABP adducts detected with the anti-M1-polyUb antibody after ATP depletion, suggesting that the probe is coupling quite selectively to these two enzymes.</p>
        <p>Next, we assessed OTULIN ABP specificity in cellular extracts on a global scale by MS. To this end, we performed biotin-PDs to enrich bio-Ub<sub>G76Dha</sub>-Ub binders. To select for covalent interactors, we optimized biotin-PD stringency. Up to 1% SDS in the washing buffer did not significantly reduce detection of OTULIN-diUb complexes, but strongly diminished the known non-covalent interaction to HOIP (<xref rid="mmc1" ref-type="supplementary-material">FigureÂ S4</xref>A; see also below). We prepared four biological replicates for each sample depicted in <xref rid="fig6" ref-type="fig">FigureÂ 6</xref>A. Besides comparing biotin-PD with and without OTULIN ABP (samples 1 and 2), we also depleted ATP by apyrase treatment to inhibit interactions that may arise from the conjugation of the probe into polyUb chains (sample 3). In addition, we checked for covalent coupling by adding the broad-spectrum DUB inhibitor PR-619 (<xref rid="bib1" ref-type="bibr">Altun etÂ al., 2011</xref>, <xref rid="bib4" ref-type="bibr">Chen etÂ al., 2014</xref>) that also prevents labeling of OTULIN by OTULIN ABP (see <xref rid="fig1" ref-type="fig">FigureÂ 1</xref>E; sample 4). As expected, whereas PR-619 abolished coupling and pull-down of OTULIN-diUb, apyrase treatment did not have an affect (<xref rid="mmc1" ref-type="supplementary-material">FigureÂ S4</xref>B).<fig id="fig6"><label>FigureÂ 6</label><caption><p>LC-MS/MS Reveals Highly Selective OTULIN Coupling and E1-Dependent Auto-Conjugation of OTULIN ABP</p><p>(A) Overview of ABP-PD samples analyzed by LC-MS/MS.</p><p>(B) Volcano plot demonstrating enrichment of identified DUBs (blue) after biotin-PD in the presence (sample 2) compared with the absence (sample 1) of OTULIN ABP. Curves depict significant enrichment or depletion, respectively. See also <xref rid="mmc1" ref-type="supplementary-material">Table S2</xref>.</p><p>(C) Volcano plot demonstrating loss of DUB binding (blue) between control (sample 3) and PR-619 (sample 4) treatments before OTULIN ABP incubation and biotin-PD. Curves depict significant enrichment or depletion, respectively.</p><p>(D) Biotin-PDs from extracts of Jurkat TÂ cells (2Â Ã 10<sup>7</sup>) were performed using the same conditions as for LC-MS/MS analyses and analyzed by western blot.</p><p>(E) Volcano plot demonstrating selective binding of DUBs (blue) and other proteins (red) to OTULIN ABP (sample 1 versus 2). Curves depict significant enrichment or depletion, respectively.</p><p>(F) Volcano plot demonstrating loss of UBA1 and UBA6 binding to OTULIN ABP upon ATP depletion (sample 2 versus 3). Curves depict significant enrichment or depletion, respectively.</p><p>(G) Extracts of HEK293 cells (6Â Ã 10<sup>5</sup> cells) were incubated with increasing amounts of His-Ub<sub>G76A</sub>-Ub or with 1Â Î¼g OTULIN ABP (45Â min, 30Â°C). Ubiquitin chain formation and OTULIN-diUb or USP5-diUb complexes were analyzed by western blot using anti-M1-polyUb and DUB-specific antibodies.</p><p>(H) Extracts of HEK293 cells (6Â Ã 10<sup>5</sup> cells) were incubated with 1Â Î¼g OTULIN ABP or 1Â Î¼g OTULIN ABPÎG76 (45Â min, 30Â°C). Labeling of OTULIN and USP5 as well as Ub chain formation was analyzed by western blot.</p><p>(I) Extracts of Jurkat TÂ cells (2Â Ã 10<sup>7</sup> cells) were treated with OTULIN ABPÎG76 before His-PD. Interactions between the new probe and the indicated proteins were analyzed by western blot.</p></caption><graphic xlink:href="gr6"/></fig></p>
        <p>We first searched for all DUBs that were identified in the samples by liquid chromatography-tandem mass spectrometry (LC-MS/MS) (<xref rid="mmc1" ref-type="supplementary-material">Table S2</xref>). Only three DUBs were identified and the statistical comparison of sample 1 (no probe) and sample 2 (OTULIN ABP) showed that OTULIN, USP5, and UCHL3 were significantly enriched in the OTULIN ABP-bound sample (volcano plot, <xref rid="fig6" ref-type="fig">FigureÂ 6</xref>B). Moreover, treatment with DUB inhibitor PR-619 led to the significant depletion of only one single DUB, OTULIN (<xref rid="fig6" ref-type="fig">FigureÂ 6</xref>C). These results suggest that despite the partial labeling of USP5 in cell extracts, USP5 and UCHL3 are primarily bound to the OTULIN ABP in a non-covalent and reversible manner. To confirm this result, we performed PD experiments treating the samples analogous to the MS experiment but using less stringent washing conditions after PD (<xref rid="fig6" ref-type="fig">FigureÂ 6</xref>D). As previously observed, the OTULIN ABP labeled OTULIN and USP5, but not UCHL3, in the extracts (<xref rid="mmc1" ref-type="supplementary-material">FigureÂ S4</xref>C). Indeed, whereas OTULIN was exclusively bound in the modified form of OTULIN-diUb, USP5 and UCHL3 were detected only in the unmodified form, revealing that these DUBs have a high affinity for the linear diUb probe, but are either not at all or just poorly coupled (<xref rid="fig6" ref-type="fig">FigureÂ 6</xref>D). Whereas previous assays showed that UCHL3 does not attack the probe, the OTULIN ABP directly labels USP5 when lysates are incubated with ABP (see <xref rid="fig5" ref-type="fig">FigureÂ 5</xref>B). Thus, combined activity profiling by MS and western blotting proves that the OTULIN ABP shows high selectivity for OTULIN with some cross-reactivity toward USP5.</p>
        <p>Moreover, when we determined global reactivity of OTULIN ABP by comparing the whole interactome enriched by biotin-PD in sample 2 versus sample 1 (<xref rid="mmc1" ref-type="supplementary-material">Table S2</xref> and <xref rid="fig6" ref-type="fig">FigureÂ 6</xref>E), only four other proteins (red) bound to OTULIN ABP besides the three DUBs (blue). These include the Ub precursor UBC, which most likely reflects detection of the probe itself, and the Ub-like modifier NEDD8. In light of the ATP-dependent Ub chain assembly in the OTULIN ABP-treated extracts it was very remarkable that the two mammalian Ub-activating enzymes, UBA1 and UBA6, were bound to the OTULIN ABP. In addition, UBA1 and UBA6 were theÂ only associated proteins whose binding was lost after ATP depletion (<xref rid="fig6" ref-type="fig">Figures 6</xref>E and 6F), which was confirmed by western blotting after biotin-PD (<xref rid="fig6" ref-type="fig">FigureÂ 6</xref>D). Interaction to all of these proteins was resistant to PR-619 treatment, indicating that they are not associating to the OTULIN ABP via OTULIN (<xref rid="mmc1" ref-type="supplementary-material">FigureÂ S4</xref>D).</p>
        <p>The ATP-dependency suggests that the C-terminal carboxyl group of the diUb probe can form a thioester bond with the E1s, just like in the first monoUb activation step in a ubiquitination cascade (<xref rid="bib5" ref-type="bibr">Chen and Pickart, 1990</xref>, <xref rid="bib33" ref-type="bibr">Martinez-Fonts and Matouschek, 2016</xref>). Since thioesters are labile under reducing conditions, no molecular-weight shift was detected for UBA1 and UBA6 by SDS-PAGE (<xref rid="mmc1" ref-type="supplementary-material">FigureÂ S4</xref>C). Nevertheless, the MS data indicate that the ATP-dependent assembly of polyUb chains by the probe may not be based on inhibition of OTULIN or other DUBs. The data instead suggest that the OTULIN ABPÂ itself is activated by E1s and conjugated to form polyUb chains. Therefore, we determined if the non-inhibitory, but cleavage-resistant, diUb protein His-Ub<sub>G76A</sub>-Ub (see <xref rid="fig4" ref-type="fig">FigureÂ 4</xref>E) is also able to form polyUb chains (<xref rid="fig6" ref-type="fig">FigureÂ 6</xref>G). As expected, Ub<sub>G76A</sub>-Ub did not label or inhibit OTULIN and USP5, but it also induced the dose-dependent assembly of Ub chains that could be detected with anti-M1-polyUb antibody (<xref rid="fig6" ref-type="fig">FigureÂ 6</xref>G). The assumption that uncleavable diUbs (such as the OTULIN ABP) are incorporated into unanchored chains was further supported by biotin-PDs, which not only precipitated and depleted free bio-Ub<sub>G76Dha</sub>-Ub probe from the cell extracts, but also removed the formed polyUb smear (<xref rid="mmc1" ref-type="supplementary-material">FigureÂ S4</xref>E). In line, the polyUb chains were strongly detected with the M1-specific anti-M1-polyUb antibody that also reacts with the bio-Ub<sub>G76Dha</sub>-Ub probe and His-Ub<sub>G76A</sub>-Ub. Since the N-terminal Tags prevent a head-to-tail linkage of the diUb probes, we performed Ub chain linkage analyses using the UbiCREST technology (<xref rid="mmc1" ref-type="supplementary-material">FigureÂ S4</xref>F) (<xref rid="bib21" ref-type="bibr">Hospenthal etÂ al., 2015</xref>). Recombinant OTULIN was coupled and inhibited by OTULIN ABP (see asterisk), but even in excess it was not able to cleave the chains, supporting the notion that the chains are assemblies of bio-Ub<sub>G76Dha</sub>-Ub adducts. Only the promiscuous DUB USP2, which cleaves all types of Ub linkages, was able to completely remove the high-molecular-weight Ub smear induced by OTULIN ABP. YOD1, which hydrolyzes primarily the atypical K6, K11, K27, K29, and K33 linkages, was able to partially reduce the Ub smear when used at high concentrations (<xref rid="mmc1" ref-type="supplementary-material">FigureÂ S4</xref>G). Thus, the data indicate that various lysine residues in the OTULIN ABP and His-Ub<sub>G76A</sub>-Ub protein can be ubiquitinated.</p>
      </sec>
      <sec id="sec2.5">
        <title>OTULIN ABPÎG76: A Specific OTULIN ABP</title>
        <p>Besides serving as the site for thioester formation by E1 enzymes, the proximal C-terminal Gly76 residue in a Ub chain is essential for USP5 activity (<xref rid="bib42" ref-type="bibr">Reyes-Turcu etÂ al., 2006</xref>). As such, we reasoned that a diUb probe lacking this C-terminal glycine should not exhibit any cross-reactivity with UBA1/UBA6 and USP5. For the synthesis of this probe we combined bacterial protein expression with chemical synthesis (<xref rid="mmc1" ref-type="supplementary-material">FigureÂ S4</xref>H). A His<sub>10</sub>-tagged diUb variant was cloned in which Gly76 of the proximal Ub was deleted and Gly76 of the distal Ub was replaced by cysteine (His<sub>10</sub>-Ub<sub>G76C</sub>-Ub<sub>ÎG76</sub>). After bacterial expression and purification, the Cys residue was completely transformed into Dha by treatment with MSH (as judged by LC-MS; <xref rid="mmc1" ref-type="supplementary-material">FigureÂ S4</xref>I) affording the desired His<sub>10</sub>-Ub<sub>G76Dha</sub>-Ub<sub>ÎG76</sub> (OTULIN ABPÎG76).</p>
        <p>When we compared the reactivity of OTULIN ABP (bio-Ub<sub>G76Dha</sub>-Ub) and OTULIN ABPÎG76 (His<sub>10</sub>-Ub<sub>G76Dha</sub>-Ub<sub>ÎG76</sub>) in extracts of HEK293 cells, both probes converted OTULIN to the higher migrating OTULIN-diUb adduct (<xref rid="fig6" ref-type="fig">FigureÂ 6</xref>H). Importantly, the OTULIN ABPÎG76 no longer showed any cross-reactivity with USP5 (<xref rid="fig6" ref-type="fig">FigureÂ 6</xref>H). His-PD showed that OTULIN ABPÎG76 still bound to USP5 and UCHL3 (<xref rid="fig6" ref-type="fig">FigureÂ 6</xref>I), confirming our MS results that these DUBs are associating largely in a non-covalent manner with the probes (compare <xref rid="fig6" ref-type="fig">Figures 6</xref>B and 6C). Gratifyingly, formation of Ub chains and binding to E1 enzymes were abolished in the case of OTULIN ABPÎG76 (<xref rid="fig6" ref-type="fig">Figures 6</xref>H and 6I), indicating that the probe can no longer be activated by UBA1/UBA6. Thus, by removing the C-terminal Gly76 in the proximal Ub moiety of our OTULIN ABP, the corresponding OTULIN ABPÎG76 becomes a specific OTULIN ABP.</p>
      </sec>
      <sec id="sec2.6">
        <title>Substrate-Bound OTULIN Associates with LUBAC</title>
        <p>The N-terminal PIM of OTULIN binds to the PUB domain of HOIP to control LUBAC activity (<xref rid="bib14" ref-type="bibr">Elliott etÂ al., 2014</xref>, <xref rid="bib47" ref-type="bibr">Schaeffer etÂ al., 2014</xref>). Size-exclusion chromatography demonstrated that recombinant OTULIN C129A, Met1-diUb, and HOIP (amino acids 1â182) can interact to form a ternary complex (<xref rid="mmc1" ref-type="supplementary-material">FigureÂ S5</xref>A). Thus, we wondered whether biotin-PD of OTULIN ABP can be used to monitor association of active substrate-bound OTULIN to HOIP, and potentially the entire LUBAC complex (<xref rid="fig7" ref-type="fig">FigureÂ 7</xref>). For this, we expressed hemagglutinin (HA)-tagged HOIP, HOIL-1, and SHARPIN, together with Flag-OTULIN, in HEK293 cells (<xref rid="fig7" ref-type="fig">FigureÂ 7</xref>A). Biotin-PD precipitated endogenous OTULIN as well as overexpressing Flag-OTULIN WT, but not catalytically inactive OTULIN C129A. HA-tagged HOIP, HOIL-1, and SHARPIN co-precipitated in similar amounts with the OTULIN-diUb adduct. Co-precipitation was slightly increased upon OTULIN overexpression, revealing that substrate-bound OTULIN is associated with LUBAC.<fig id="fig7"><label>FigureÂ 7</label><caption><p>Association of Substrate-Bound OTULIN with LUBAC</p><p>(A) HA-tagged LUBAC components and Flag-tagged OTULIN were co-transfected into HEK293 cells as indicated. Biotin-PD of OTULIN-diUb after OTULIN ABP incubation in cell extracts (â¼1Â Ã 10<sup>7</sup> cells) was analyzed for the association of transfected LUBAC proteins by western blot.</p><p>(B) Jurkat TÂ cells were stimulated with TNF-Î± (20Â ng/mL), and lysates (2.5Â Ã 10<sup>5</sup> cells) were incubated with OTULIN ABP (1Â Î¼g) and analyzed for changes in OTULIN activity by western blot.</p><p>(C) Biotin-PD of OTULIN ABP was performed as in (A) from extracts of TNF-Î±-stimulated Jurkat TÂ cells (2Â Ã 10<sup>7</sup> cells, 4Â Î¼g OTULIN ABP). Interaction of endogenous OTULIN-diUb and LUBAC was assessed by western blot.</p><p>(D) Cell extracts of Jurkat TÂ cells (+/â TNF-Î± stimulation) were subjected to OTULIN ABP incubation. OTULIN, HOIP, HOIL-1, and SHARPIN amounts were determined by western blotting prior (input) and after (supernatant) biotin-PD of OTULIN-diUb complexes.</p><p>(E) The majority of LUBAC subunits is not associated with OTULIN-diUb complexes. Biotin-PD of OTULIN-diUb complexes from extracts of unstimulated Jurkat TÂ cells (2Â Ã 10<sup>7</sup> cells) was performed as in (C). Levels of LUBAC subunits and OTULIN were quantified in the input and the supernatant. The quantified relative amounts of âfreeâ OTULIN-diUb unbound proteins are depicted. Data represent the meanÂ Â± SD of six independent experiments.</p><p>(F) Extracts of Jurkat TÂ cells (2Â Ã 10<sup>7</sup> cells/sample) were treated with 4Â Î¼g OTULIN ABPÎG76 before His-PD. Binding of LUBAC components after PD was analyzed by western blot.</p></caption><graphic xlink:href="gr7"/></fig></p>
        <p>Generation of M1-linked Ub chains drives TNFR-induced NF-ÎºB signaling (<xref rid="bib45" ref-type="bibr">Sasaki and Iwai, 2015</xref>). Therefore, we determined whether OTULIN activity and OTULIN association with LUBAC is altered upon TNF-Î± stimulation. Stimulation of HEK293 cells with TNF-Î± for 10 to 90Â min led to NF-ÎºB activation as evident by IÎºBÎ± phosphorylation and degradation (<xref rid="fig7" ref-type="fig">FigureÂ 7</xref>B). However, activity of OTULIN was not impaired upon TNF-Î± stimulation, as apparent from the unchanged formation of OTULIN-diUb complexes in extracts of TNF-Î±-treated HEK293 cells. To determine if stimulation alters the binding of endogenous OTULIN to LUBAC, we performed biotin-PD of OTULIN-diUb complexes from the extracts of Jurkat TÂ cells prior to or after TNF-Î± treatment (<xref rid="fig7" ref-type="fig">FigureÂ 7</xref>C). The three LUBAC components co-precipitated with substrate-bound OTULIN, but the amounts of HOIP, HOIL-1, or SHARPIN did not decrease after TNF-Î± stimulation (<xref rid="fig7" ref-type="fig">FigureÂ 7</xref>C). To determine the amounts of LUBAC associated with the OTULIN ABP, we directly compared the levels of HOIP, HOIL-1, and SHARPIN by loading equal volumes of the lysates before (input) and after biotin-PD (supernatant) (<xref rid="fig7" ref-type="fig">FigureÂ 7</xref>D). The PD reduced the amounts of LUBAC in the supernatant, but TNF-Î± stimulation did not affect association of substrate-bound OTULIN to LUBAC. To analyze more closely how much LUBAC is associated with substrate-coupled OTULIN, we quantified the concentration of HOIP, HOIL-1, and SHARPIN in the input (total LUBAC) and the supernatant (âfreeâ OTULIN-diUb unbound LUBAC) in extracts from unstimulated Jurkat TÂ cells (<xref rid="fig7" ref-type="fig">FigureÂ 7</xref>E). Whereas the biotin-PD depleted more than 80% of active OTULIN, only approximately 25% of each LUBAC subunit were removed from the extracts by co-precipitation. This means that the majority of HOIP, HOIL-1, and SHARPIN (â¼75%) were not associated with substrate-bound OTULIN. <italic>InÂ vitro</italic> experiments already indicated that the ternary HOIP-OTULIN-diUb complex is quite stable in gel filtration chromatography (<xref rid="mmc1" ref-type="supplementary-material">FigureÂ S5</xref>A). To make sure that the partial binding of LUBAC to substrate-bound OTULIN is not resulting from a high dissociation rate in PD experiments, we monitored the association in successive washing steps (<xref rid="mmc1" ref-type="supplementary-material">FigureÂ S5</xref>B). By increasing the number of washing steps, the detected amounts of OTULIN-diUb and bound LUBAC did not alter, indicating that the partial LUBAC binding to OTULIN-diUb is not a result of constant dissociation of the complex. Finally, to ascertain that the observed OTULIN-LUBAC association is independent of USP5 coupling and ATP-dependent conjugation of Ub chains by the probe, we verified that association of active OTULIN with the LUBAC was also detectable with the specific OTULIN ABPÎG76 (<xref rid="fig7" ref-type="fig">FigureÂ 7</xref>F). The data indicate that separate LUBAC-associated complexes exist in cells that may be subject to differential regulation by different DUBs.</p>
      </sec>
    </sec>
    <sec id="sec3">
      <title>Discussion</title>
      <p>With the synthesis of bio-Ub<sub>G76Dha</sub>-Ub (OTULIN ABP) and His-Ub<sub>G76Dha</sub>-Ub<sub>ÎG76</sub> (OTULIN ABP ÎG76) we provide the first substrate-based diUb probes that covalently label the M1-specific DUB OTULIN. Together with the previously developed diUb ABP panel that comprises all linkage types (<xref rid="bib38" ref-type="bibr">Mulder etÂ al., 2014</xref>), the OTULIN ABP completes the toolkit of diUb-based DUB probes targeting the linkage specificity determining S1 and S1â² sites of an enzyme.</p>
      <p>The design of the OTULIN probes is based on the assumption that, despite some rigid constraints for the binding of OTULIN to diUb, position Gly76 in the distal Ub moiety may be amendable for a nucleophilic attack by the catalytic Cys129 in OTULIN (<xref rid="bib26" ref-type="bibr">Keusekotten etÂ al., 2013</xref>). By determining the structure of OTULIN in complex with bio-Ub<sub>G76Dha</sub>-Ub we confirmed that the electrophilic Dha76 covalently couples to OTULIN Cys129. In contrast, the OTULIN-diUb co-structures (PDB: <ext-link ext-link-type="uri" xlink:href="pdb:3ZNZ" id="intref0015">3ZNZ</ext-link>) clearly indicated that M1 of proximal Ub moiety is pointing away from the active site (<xref rid="fig3" ref-type="fig">FigureÂ 3</xref>C), and, in line, the exchange of M1 to Dha failed to react with OTULIN (<xref rid="bib20" ref-type="bibr">Haj-Yahya etÂ al., 2014</xref>). Our structural analysis of the substrate bound to active WT OTULIN underscores the rigid constraints for OTULIN-diUb binding and thus the hydrolysis of M1-linked Ub leading to the high specificity of the enzyme. The mutation of G76A in the distal Ub moiety severely reduced the affinity to OTULIN and completely abrogated cleavage of diUb by OTULIN (<xref rid="fig4" ref-type="fig">Figures 4</xref>E and 4F) (<xref rid="bib26" ref-type="bibr">Keusekotten etÂ al., 2013</xref>). Indeed, there is very little space in the active site, and the alanine side chain at position Gly76 potentially clashes with catalytic Cys129 of OTULIN (<xref rid="fig3" ref-type="fig">Figures 3</xref>C and <xref rid="fig4" ref-type="fig">4</xref>C). Nevertheless, despite the apparently lower affinity compared with the native linkage, the presence of the electrophile Dha is sufficient for being captured by the Cys129 of OTULIN. Thus, formation of the covalent OTULIN-diUb product is driven by the Dha electrophile and not so much by the affinity of OTULIN for the probe.</p>
      <p>Most striking was the high selectivity of bio-Ub<sub>G76Dha</sub>-Ub for the DUB OTULIN, as revealed by direct DUB assays <italic>inÂ vitro</italic> as well as by binding studies using MS (<xref rid="fig4" ref-type="fig">Figures 4</xref>, <xref rid="fig5" ref-type="fig">5</xref>, and <xref rid="fig6" ref-type="fig">6</xref>). Surprisingly, the USP DUBs USP2, USP21, and CYLD, which have been shown to cleave M1-linked Ub chains, did not react with Ub<sub>G76Dha</sub>-Ub (<xref rid="fig4" ref-type="fig">Figures 4</xref> and <xref rid="fig5" ref-type="fig">5</xref>). USP2 and USP21 are promiscuous and can cleave all types of Ub chains. The fact that they are not labeled by the OTULIN ABP may be attributed to their low activity toward M1-linkages (<xref rid="bib3" ref-type="bibr">Bremm etÂ al., 2010</xref>, <xref rid="bib17" ref-type="bibr">Faesen etÂ al., 2011</xref>, <xref rid="bib30" ref-type="bibr">Komander etÂ al., 2009b</xref>, <xref rid="bib53" ref-type="bibr">Virdee etÂ al., 2010</xref>, <xref rid="bib58" ref-type="bibr">Ye etÂ al., 2011</xref>). CYLD efficiently cleaves M1- or K63-linked Ub chains (<xref rid="bib46" ref-type="bibr">Sato etÂ al., 2015</xref>), but it still did not react with the probe. Structural comparisons of diUb binding to OTULIN or CYLD reveal that the narrow channel in CYLD, which accommodates the C-terminal tail of distal Ub and thus locates the scissile bond near the active site, may not tolerate introduction of an alanine or Dha at the position G76 (<xref rid="bib28" ref-type="bibr">Komander etÂ al., 2008</xref>, <xref rid="bib41" ref-type="bibr">Renatus etÂ al., 2006</xref>, <xref rid="bib46" ref-type="bibr">Sato etÂ al., 2015</xref>). The residues contacting the tail of the distal Ub are well conserved in other USPs such as USP2, USP7, USP14, and USP21 (<xref rid="bib23" ref-type="bibr">Hu etÂ al., 2002</xref>, <xref rid="bib24" ref-type="bibr">Hu etÂ al., 2005</xref>, <xref rid="bib58" ref-type="bibr">Ye etÂ al., 2011</xref>). Accordingly, USP21 and CYLD are unable to cleave the Ub<sub>G76A</sub>-Ub substrate, indicating that Gly76 of the distal Ub is essential for recognition and cleavage of linear diUb by USPs.</p>
      <p>Under stringent conditions, only three DUBs (OTULIN, USP5, and UCHL3) were identified by LC-MS/MS in PD experiments with bio-Ub<sub>G76Dha</sub>-Ub (<xref rid="fig6" ref-type="fig">FigureÂ 6</xref>). Remarkably, only OTULIN binding was lost after treatment with the broad-spectrum DUB inhibitor PR-619, which also inhibits USP5 and UCHL3 (<xref rid="bib1" ref-type="bibr">Altun etÂ al., 2011</xref>). Thus, the binding of USP5 and UCHL3 to OTULIN ABP is largely non-covalent and reversible. In contrast to the linear probe discussed here, any of the internal Lys-linked ABPs label a variety of DUBs in cell lysates (<xref rid="bib38" ref-type="bibr">Mulder etÂ al., 2014</xref>). This is due to the rather non-selective cleavage activity of, in particular, USP domain enzymes, of which more than 50 can be present in human cells (<xref rid="bib27" ref-type="bibr">Komander etÂ al., 2009a</xref>). The efficient labeling of OTULIN reflects that the OTU DUB is unique in its specific recognition and strong catalytic activity toward M1-linked Ub chains (<xref rid="bib36" ref-type="bibr">Mevissen etÂ al., 2013</xref>). The non-covalent binding of OTULIN ABP to UCHL3 is most likely due to the high abundance of this enzyme. Moreover, efficient association of Ub dimers and UCHL3 without cleavage has been observed before <italic>inÂ vitro</italic> and in cells (<xref rid="bib51" ref-type="bibr">Setsuie etÂ al., 2009</xref>). Interestingly, USP5 also largely binds reversibly to the probe, which may be due to the ability of the ZnF-ubiquitin binding domain to capture free Ub chains (<xref rid="bib43" ref-type="bibr">Reyes-Turcu etÂ al., 2008</xref>). However, direct DUB detection in western blots clearly shows that the OTULIN ABP can couple to USP5. It is not quite clear why the USP5-diUb product wasÂ not detected in biotin-PD assays, but structural constraints due to the large catalytic cavity of USP5 may preclude accessibility of the streptavidin beads after the attachment of biotin-diUb to USP5 (<xref rid="bib42" ref-type="bibr">Reyes-Turcu etÂ al., 2006</xref>). The C-terminal di-glycine motif of the most proximal Ub in a polyUb chain was shown to allosterically activate USP5 and to thereby enable cleavage of unanchored Ub chains (<xref rid="bib42" ref-type="bibr">Reyes-Turcu etÂ al., 2006</xref>, <xref rid="bib43" ref-type="bibr">Reyes-Turcu etÂ al., 2008</xref>). Indeed, by generating a probe that lacks the very C-terminal glycine residue (His-Ub<sub>G76Dha</sub>Ub<sub>ÎG76</sub>, OTULIN ABPÎG76), we were able to eliminate cross-reactivity with USP5, yielding a DUB probe that is specific for one single enzyme of the entire DUB class of cysteine proteases.</p>
      <p>Also, we detected proteome-wide minimal cross-reactivities of OTULIN ABP. Most striking was the energy-dependent generation of polyOTULIN ABP chains, which are detectable with an M1-specific Ub antibody. The identified ATP-dependent interaction of the E1 enzymes UBA1 or UBA6 with OTULIN ABP suggested that generation of these probe adducts is not connected to OTULIN inhibition or the enhanced conjugation of M1-linked Ub chains, as observed in OTULIN KO cells (<xref rid="bib6" ref-type="bibr">Damgaard etÂ al., 2016</xref>). Since the N termini of the diUbs are occupied, internal lysine residues must function as attachment sites to form unanchored branched Ub chains. Multiple lysines in the diUb probe can serve as coupling sites and accordingly USP2 and YOD1, which can cleave a number of different Ub linkages, lead to complete and partial digestion of the Ub chains, respectively. Currently, it is unclear if the finding of the <italic>inÂ vitro</italic> synthesis of such artificial and branched chains is physiologically relevant, but unanchored Ub dimers and chains exist in cells and thus they may be utilized for polyUb conjugation (<xref rid="bib5" ref-type="bibr">Chen and Pickart, 1990</xref>, <xref rid="bib33" ref-type="bibr">Martinez-Fonts and Matouschek, 2016</xref>, <xref rid="bib52" ref-type="bibr">Strachan etÂ al., 2012</xref>). For diUb-based ABP, it is important to note that the auto-conjugation can be abolished by simply deleting the C-terminal Gly76, which prevents E1-catalyzed transfer.</p>
      <p>Recently, structural studies on the K11-linkage-specific OTU DUB Cezanne demonstrated the benefits of substrate-guided DUB probes (<xref rid="bib37" ref-type="bibr">Mevissen etÂ al., 2016</xref>). The K11-diUb ABP reacted with the Cezanne catalytic triad enabling crystallization of an otherwise unstable and highly dynamic enzyme-substrate complex, demonstrating that the enzyme can accommodate the ABP chemistry in the active site (<xref rid="bib37" ref-type="bibr">Mevissen etÂ al., 2016</xref>). Here, we show how functional analyses of DUBs in cells can profit from selective probes as the OTULIN ABP (<xref rid="fig7" ref-type="fig">FigureÂ 7</xref>). By nearly completely depleting substrate-bound OTULIN by biotin-PD, we show that all LUBAC subunits are associated at equivalent levels (20%â30%) with substrate-bound OTULIN. However, our data also indicate that the majority of LUBAC (â¼75%) is not stably binding to OTULIN in cell extracts. In line, a previous report demonstrated that a fraction of LUBAC is not associated with OTULIN (<xref rid="bib14" ref-type="bibr">Elliott etÂ al., 2014</xref>). It was suggested that the OTULIN-LUBAC interaction can be regulated by phosphorylation of the PIM of OTULIN (<xref rid="bib14" ref-type="bibr">Elliott etÂ al., 2014</xref>, <xref rid="bib47" ref-type="bibr">Schaeffer etÂ al., 2014</xref>), but so far we have no evidence to suggest that the association is altered upon TNF-Î± stimulation. Also, OTULIN activity does not change upon TNF-Î± stimulation. Certainly, the affinity to substrate-free OTULIN as well as k<sub>on</sub>/k<sub>off</sub> rates may considerably influence the overall binding and regulation of LUBAC by OTULIN. However, our data strengthen the model that distinctÂ LUBAC-DUB complexes exist and are susceptible to differential regulation, which is congruent with the observation that CYLD/SPATA2-LUBAC, but not OTULIN-LUBAC complexes, are recruited to the TNFR complex to counteract LUBAC activity post-induction (<xref rid="bib13" ref-type="bibr">Elliott etÂ al., 2016</xref>, <xref rid="bib32" ref-type="bibr">Kupka etÂ al., 2016</xref>, <xref rid="bib50" ref-type="bibr">Schlicher etÂ al., 2016</xref>, <xref rid="bib55" ref-type="bibr">Wagner etÂ al., 2016</xref>). Further, ablation of OTULIN but not CYLD was reported to promote significant accumulation of linear Ub chains in the absence of any stimulation (<xref rid="bib6" ref-type="bibr">Damgaard etÂ al., 2016</xref>, <xref rid="bib8" ref-type="bibr">Draber etÂ al., 2015</xref>).</p>
      <p>Interestingly, effects of OTULIN deficiency are highly cell-type specific. While absence of OTULIN induces spontaneous M1-linked polyubiquitination and NF-ÎºB activation in myeloid cells, OTULIN deficiency in T and B cells results in loss of LUBAC (<xref rid="bib6" ref-type="bibr">Damgaard etÂ al., 2016</xref>). The OTULIN ABP will facilitate addressing potential cell-type-specific differences in LUBAC binding and regulation by OTULIN. Moreover, our OTULIN ABP will help to characterize the physiological roles of OTULIN and in how far its functions go beyond counteracting LUBAC activity. Finally, hypomorphic mutations of OTULIN cause severe auto-inflammatory syndromes in humans (<xref rid="bib6" ref-type="bibr">Damgaard etÂ al., 2016</xref>, <xref rid="bib59" ref-type="bibr">Zhou etÂ al., 2016</xref>) and detection of active OTULIN may be used to monitor defective DUB activity <italic>inÂ vivo</italic>.</p>
    </sec>
    <sec id="sec4">
      <title>Significance</title>
      <p>
        <bold>Activity-based probes (ABPs) are important tools to study enzyme activities <italic>inÂ vitro</italic> and <italic>inÂ vivo</italic>. Different probes for deubiquitinating enzymes (DUBs) have been introduced, but in general these probes lack selectivity, because they react with a broader panel of ubiquitin hydrolases. We used complete chemical synthesis to generate a biotinylated diUb-based probe in which the C-terminal glycine 76 of the distal ubiquitin was replaced by a Dha electrophile (bio-Ub</bold>
        <sub>
          <bold>G76Dha</bold>
        </sub>
        <bold>-Ub). Indeed, the probe represents the first probe that recognizes and covalently labels OTULIN and thus was named OTULIN ABP. Notably, OTULIN ABP is highly selective and showed no cross-reactivity in mass spectrometry analyses. Among DUBs, the only discernible cross-reactivity was toward USP5 (Isopeptidase T), which is capable of disassembling any type of ubiquitin chain from the C terminus. Proteome-wide interaction analyses revealed ATP-dependent activation of bio-Ub</bold>
        <sub>
          <bold>G76Dha</bold>
        </sub>
        <bold>-Ub by E1Â Ub-activating enzymes UBA1 and UBA6, resulting in (auto-)polyubiquitination of the probe. Both, USP5 labeling and probe auto-conjugation are abolished by deleting glycine 76 of the proximal ubiquitin (Ub</bold>
        <sub>
          <bold>G76Dha</bold>
        </sub>
        <bold>-Ub</bold>
        <sub>
          <bold>ÎG76</bold>
        </sub>
        <bold>), yielding the specific OTULIN ABPÎG76. Using our OTULIN ABP we demonstrate that OTULIN is constitutively active in cells, and that substrate-bound OTULIN associates with the linear ubiquitin chain assembly complex (LUBAC). This study highlights that it is possible to generate a specific ABP for the specific linear ubiquitin hydrolase OTULIN. Overall, the here presented OTULIN ABP can be a valuable tool for assessing OTULIN activity, localization after fractionation of cellular compartments, and association with other proteins, as well as its function in physiological and pathological settings.</bold>
      </p>
    </sec>
    <sec id="sec5">
      <title>STARâMethods</title>
      <sec id="sec5.1">
        <title>Key Resources Table</title>
        <p>
          <table-wrap id="undtbl1" position="float">
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th>REAGENT or RESOURCE</th>
                  <th>SOURCE</th>
                  <th>IDENTIFIER</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td colspan="3">
                    <bold>Antibodies</bold>
                  </td>
                </tr>
                <tr>
                  <td colspan="3">
                    <hr/>
                  </td>
                </tr>
                <tr>
                  <td>Goat polyclonal anti-Actin (I-19) HRP</td>
                  <td>Santa Cruz Biotechnology</td>
                  <td>Cat#sc1616 HRP; RRID: N/A</td>
                </tr>
                <tr>
                  <td>Mouse monoclonal anti-CYLD (E10)</td>
                  <td>Santa Cruz Biotechnology</td>
                  <td>Cat#sc-74435; RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_1122022" id="intref0020">AB_1122022</ext-link></td>
                </tr>
                <tr>
                  <td>Mouse monoclonal anti-ubiquitin (P4D1)</td>
                  <td>Santa Cruz Biotechnology</td>
                  <td>Cat#sc-8017; RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_2315523" id="intref0025">AB_2315523</ext-link></td>
                </tr>
                <tr>
                  <td>Goat anti-biotin</td>
                  <td>Cell Signaling Technology</td>
                  <td>Cat#7075; RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_330923" id="intref0030">AB_330923</ext-link></td>
                </tr>
                <tr>
                  <td>Rabbit polyclonal anti-OTULIN</td>
                  <td>Cell Signaling Technology</td>
                  <td>Cat#14127; RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_2576213" id="intref0035">AB_2576213</ext-link></td>
                </tr>
                <tr>
                  <td>Mouse monoclonal anti-IÎºBÎ±</td>
                  <td>Cell Signaling Technology</td>
                  <td>Cat#4814; RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_390781" id="intref0040">AB_390781</ext-link></td>
                </tr>
                <tr>
                  <td>Mouse monoclonal anti-phospho-IÎºBÎ± (Ser32/36) (5A5)</td>
                  <td>Cell Signaling Technology</td>
                  <td>Cat#9246; RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_2151442" id="intref0045">AB_2151442</ext-link></td>
                </tr>
                <tr>
                  <td>Rabbit polyclonal anti-OTUB1</td>
                  <td>Bethyl Laboratories</td>
                  <td>Cat#A302-917A; RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_10663033" id="intref0050">AB_10663033</ext-link></td>
                </tr>
                <tr>
                  <td>Rabbit polyclonal anti-USP5/IsoT</td>
                  <td>Bethyl Laboratories</td>
                  <td>Cat#A301-542A; RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_1040028" id="intref0055">AB_1040028</ext-link></td>
                </tr>
                <tr>
                  <td>Mouse monoclonal anti-FLAG M2</td>
                  <td>Sigma-Aldrich</td>
                  <td>Cat#F3165; RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_259529" id="intref0060">AB_259529</ext-link></td>
                </tr>
                <tr>
                  <td>Sheep polyclonal anti-HOIL-1/RBCK1</td>
                  <td>MRC PPU Reagents and Services</td>
                  <td>Cat#S105D; RRID: N/A</td>
                </tr>
                <tr>
                  <td>Rabbit polyclonal anti-HOIP/RNF31</td>
                  <td>Abcam</td>
                  <td>Cat#ab85294; RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_1925400" id="intref0065">AB_1925400</ext-link></td>
                </tr>
                <tr>
                  <td>Rabbit polyclonal anti-SHARPIN</td>
                  <td>Proteintech</td>
                  <td>Cat#14626-1-AP; RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_2187734" id="intref0070">AB_2187734</ext-link></td>
                </tr>
                <tr>
                  <td>Rabbit monoclonal anti-M1-polyUb</td>
                  <td>Millipore</td>
                  <td>Cat#MABS19; RRID:<ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_2576212" id="intref0075">AB_2576212</ext-link></td>
                </tr>
                <tr>
                  <td>Human monoclonal anti-M1-polyUb</td>
                  <td>Genentech</td>
                  <td>Matsumoto etÂ al.; RRID: N/A</td>
                </tr>
                <tr>
                  <td>Rat anti-HA (3F1)</td>
                  <td>Core facility monoclonal antibodies Helmholtz Zentrum MÃ¼nchen</td>
                  <td>RRID: N/A</td>
                </tr>
                <tr>
                  <td colspan="3">
                    <hr/>
                  </td>
                </tr>
                <tr>
                  <td colspan="3">
                    <bold>Bacterial Strains</bold>
                  </td>
                </tr>
                <tr>
                  <td colspan="3">
                    <hr/>
                  </td>
                </tr>
                <tr>
                  <td><italic>E.Â coli</italic> BL21-CodonPlus (DE3)-RIPL</td>
                  <td>Agilent Technologies</td>
                  <td>Cat#230280</td>
                </tr>
                <tr>
                  <td>One Shot TOP10 Chemically Competent <italic>E.Â coli</italic></td>
                  <td>Thermo Fisher Scientific</td>
                  <td>Cat#C404003</td>
                </tr>
                <tr>
                  <td colspan="3">
                    <hr/>
                  </td>
                </tr>
                <tr>
                  <td colspan="3">
                    <bold>Chemicals, Peptides, and Recombinant Proteins</bold>
                  </td>
                </tr>
                <tr>
                  <td colspan="3">
                    <hr/>
                  </td>
                </tr>
                <tr>
                  <td>Recombinant human TNF alpha</td>
                  <td>biomol</td>
                  <td>Cat#50435.50</td>
                </tr>
                <tr>
                  <td>Recombinant M1-linked tetraUb chains</td>
                  <td>Enzo Life Sciences</td>
                  <td>Cat#BML-UW0785-0100</td>
                </tr>
                <tr>
                  <td>Recombinant human diUb chains (K48-linked)</td>
                  <td>R&amp;D Systems</td>
                  <td>Cat#UC-200-100</td>
                </tr>
                <tr>
                  <td>Recombinant human His<sub>6</sub>-CYLD Isoform 1</td>
                  <td>R&amp;D Systems</td>
                  <td>Cat#E-556-050</td>
                </tr>
                <tr>
                  <td>Recombinant human USP21<sub>cat</sub></td>
                  <td>Laboratory of Titia Sixma</td>
                  <td>(<xref rid="bib17" ref-type="bibr">Faesen etÂ al., 2011</xref>)</td>
                </tr>
                <tr>
                  <td>Recombinant human GST-YOD1</td>
                  <td>Laboratory of Daniel Krappmann</td>
                  <td>(<xref rid="bib49" ref-type="bibr">Schimmack etÂ al., 2017</xref>)</td>
                </tr>
                <tr>
                  <td>Deconjugating Enzyme Set</td>
                  <td>R&amp;D Systems</td>
                  <td>Cat#K-E10B</td>
                </tr>
                <tr>
                  <td>UbiCREST Deubiquitinase Enzyme Set</td>
                  <td>R&amp;D Systems</td>
                  <td>Cat#K-400</td>
                </tr>
                <tr>
                  <td>Biotin-Ahx-Ub-PA</td>
                  <td>UbiQ</td>
                  <td>Cat#UbiQ-076</td>
                </tr>
                <tr>
                  <td>Fmoc protected amino acids</td>
                  <td>ChemImpex</td>
                  <td/>
                </tr>
                <tr>
                  <td>PyBOP</td>
                  <td>ChemImpex</td>
                  <td>Cat#02276, CAS 128625-52-5</td>
                </tr>
                <tr>
                  <td>HBTU</td>
                  <td>ChemImpex</td>
                  <td>Cat#02011 CAS 94790-37-1</td>
                </tr>
                <tr>
                  <td>D-Biotin</td>
                  <td>ChemImpex</td>
                  <td>Cat#00033, CAS 58-85-5</td>
                </tr>
                <tr>
                  <td>1,1,1,3,3,3-Hexafluoroisopropanol</td>
                  <td>ChemImpex</td>
                  <td>Cat#00080, CAS 920-66-1</td>
                </tr>
                <tr>
                  <td>Fmoc-Gly-TentaGel Trt R resin (0.18Â mmol/g)</td>
                  <td>Rapp</td>
                  <td>Cat#RA1213</td>
                </tr>
                <tr>
                  <td><italic>N</italic>-Methyl-2-Pyrrolidone (peptide grade)</td>
                  <td>Biosolve</td>
                  <td>Cat#13563304, CAS 872-50-4</td>
                </tr>
                <tr>
                  <td>Acetonitrile (HPLC grade)</td>
                  <td>Biosolve</td>
                  <td>Cat#01201304, CAS 75-05-8</td>
                </tr>
                <tr>
                  <td>Dichloromethane (S/amylene, peptide grade)</td>
                  <td>Biosolve</td>
                  <td>Cat#13793302, CAS 75-09-2</td>
                </tr>
                <tr>
                  <td><italic>N,N</italic>-diisopropylethylamine (peptide grade)</td>
                  <td>Biosolve</td>
                  <td>Cat#04153301, CAS 7087-68-5</td>
                </tr>
                <tr>
                  <td>Water (HPLC grade)</td>
                  <td>Biosolve</td>
                  <td>Cat#23210605, CAS 7732-18-5</td>
                </tr>
                <tr>
                  <td>Water (LCMS grade)</td>
                  <td>Biosolve</td>
                  <td>Cat#23217802, CAS 7732-18-5</td>
                </tr>
                <tr>
                  <td>Piperidine (peptide grade)</td>
                  <td>Biosolve</td>
                  <td>Cat#16183301, CAS 110-89-4</td>
                </tr>
                <tr>
                  <td>Diethyl ether (AR grade)</td>
                  <td>Biosolve</td>
                  <td>Cat#05280502, CAS 60-29-7</td>
                </tr>
                <tr>
                  <td>n-Pentane (AR grade)</td>
                  <td>Biosolve</td>
                  <td>Cat#16050502, CAS 109-66-0</td>
                </tr>
                <tr>
                  <td>Dimethylsulfoxide (AR)</td>
                  <td>Biosolve</td>
                  <td>Cat#04470501, CAS 67-68-5</td>
                </tr>
                <tr>
                  <td>Trifluoroacetic acid (peptide grade)</td>
                  <td>Biosolve</td>
                  <td>Cat#20233332, CAS 76-05-1</td>
                </tr>
                <tr>
                  <td>Formic acid (99%, LCMS grade)</td>
                  <td>Biosolve</td>
                  <td>Cat#6914143, CAS 64-18-6</td>
                </tr>
                <tr>
                  <td><italic>N,N</italic>-Dimethylformamide (peptide grade)</td>
                  <td>Biosolce</td>
                  <td>Cat#04193301, CAS 68-12-2</td>
                </tr>
                <tr>
                  <td>Triisopropylsilane (98%)</td>
                  <td>Sigma Aldrich</td>
                  <td>Cat#233781, CAS 6485-79-6</td>
                </tr>
                <tr>
                  <td>Phenol (BioXtra, â¥99.5% GC)</td>
                  <td>Sigma Aldrich</td>
                  <td>Cat#P5566, CAS 108-95-2</td>
                </tr>
                <tr>
                  <td>Methyl 3-mercaptopropionate (98%)</td>
                  <td>Sigma Aldrich</td>
                  <td>Cat#108987, CAS 2935-90-2</td>
                </tr>
                <tr>
                  <td>4-Mercaptophenylacetic acid (97%)</td>
                  <td>Sigma Aldrich</td>
                  <td>Cat#653152, CAS 39161-84-7</td>
                </tr>
                <tr>
                  <td>HOBt</td>
                  <td>Sigma Aldrich</td>
                  <td>Cat#54802, CAS 123333-53-9</td>
                </tr>
                <tr>
                  <td><italic>O</italic>-mesitylenesulfonylhydroxylamine</td>
                  <td>(<xref rid="bib2" ref-type="bibr">Bernardes etÂ al., 2008</xref>)</td>
                  <td>CAS 36016-40-7</td>
                </tr>
                <tr>
                  <td>PR-619, DUB Inhibitor V</td>
                  <td>Merck Chemicals</td>
                  <td>Cat#662141; CAS 21645-32-1</td>
                </tr>
                <tr>
                  <td>cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail</td>
                  <td>Roche</td>
                  <td>Cat#11836170001</td>
                </tr>
                <tr>
                  <td>Pierce High Capacitiy Streptavidin Agarose</td>
                  <td>Thermo Fisher Scientific</td>
                  <td>Cat#20357</td>
                </tr>
                <tr>
                  <td>Strep-Tactin Sepharose 50% suspension</td>
                  <td>IBA</td>
                  <td>Cat#2-1201-010</td>
                </tr>
                <tr>
                  <td>Protino<sup>Â®</sup> Ni-NTA Agarose</td>
                  <td>MACHEREY-NAGEL</td>
                  <td>Cat# 745400.100</td>
                </tr>
                <tr>
                  <td>Roti-Load 1, 4x conc.</td>
                  <td>Carl Roth</td>
                  <td>Cat#K929.1</td>
                </tr>
                <tr>
                  <td><italic>E.coli</italic> recombinant Apyrase</td>
                  <td>New England Biolabs</td>
                  <td>Cat#M0398L</td>
                </tr>
                <tr>
                  <td>Sequence Grade Modified Trypsin</td>
                  <td>Promega</td>
                  <td>Cat#V5111</td>
                </tr>
                <tr>
                  <td colspan="3">
                    <hr/>
                  </td>
                </tr>
                <tr>
                  <td colspan="3">
                    <bold>Critical Commercial Assays</bold>
                  </td>
                </tr>
                <tr>
                  <td colspan="3">
                    <hr/>
                  </td>
                </tr>
                <tr>
                  <td>Pierce Silver Stain Kit</td>
                  <td>Life Technologies</td>
                  <td>Cat#24612</td>
                </tr>
                <tr>
                  <td colspan="3">
                    <hr/>
                  </td>
                </tr>
                <tr>
                  <td colspan="3">
                    <bold>Deposited Data</bold>
                  </td>
                </tr>
                <tr>
                  <td colspan="3">
                    <hr/>
                  </td>
                </tr>
                <tr>
                  <td>Structure OTULIN-bio-Ub<sub>G76Dha</sub>-Ub complex</td>
                  <td>This paper</td>
                  <td>PDB: <ext-link ext-link-type="uri" xlink:href="pdb:5OE7" id="intref0080">5OE7</ext-link></td>
                </tr>
                <tr>
                  <td>Structure OTULIN OTU domain (C129A) in complex with M1-linked diubiquitin</td>
                  <td>(<xref rid="bib26" ref-type="bibr">Keusekotten etÂ al., 2013</xref>)</td>
                  <td>PDB:<ext-link ext-link-type="uri" xlink:href="pdb:3ZNZ" id="intref0085">3ZNZ</ext-link></td>
                </tr>
                <tr>
                  <td>Structure zCYLD USP domain (C596S) in complex with M1-linked diubiquitin</td>
                  <td>
                    <xref rid="bib46" ref-type="bibr">Sato etÂ al., 2015</xref>
                  </td>
                  <td>PDB: <ext-link ext-link-type="uri" xlink:href="pdb:3WXE" id="intref0090">3WXE</ext-link></td>
                </tr>
                <tr>
                  <td>Mass spectrometry data</td>
                  <td>ProteomeXchange</td>
                  <td>
                    <ext-link ext-link-type="uri" xlink:href="pride:PXD006868" id="intref0095">PXD006868</ext-link>
                  </td>
                </tr>
                <tr>
                  <td colspan="3">
                    <hr/>
                  </td>
                </tr>
                <tr>
                  <td colspan="3">
                    <bold>Experimental Models: Cell Lines</bold>
                  </td>
                </tr>
                <tr>
                  <td colspan="3">
                    <hr/>
                  </td>
                </tr>
                <tr>
                  <td>HEK293 cells</td>
                  <td>DSMZ</td>
                  <td>RRID: CVCL_0045</td>
                </tr>
                <tr>
                  <td>Jurkat TÂ cells</td>
                  <td>N/A</td>
                  <td>N/A</td>
                </tr>
                <tr>
                  <td colspan="3">
                    <hr/>
                  </td>
                </tr>
                <tr>
                  <td colspan="3">
                    <bold>Recombinant DNA</bold>
                  </td>
                </tr>
                <tr>
                  <td colspan="3">
                    <hr/>
                  </td>
                </tr>
                <tr>
                  <td>pASK-IBA3(+)</td>
                  <td>IBA</td>
                  <td>Cat#2-1402-000</td>
                </tr>
                <tr>
                  <td>pASK-IBA3 OTULIN<sub>cat</sub>-Strep-tag II WT (cat: residues 80-352)</td>
                  <td>This paper</td>
                  <td>N/A</td>
                </tr>
                <tr>
                  <td>pASK-IBA3 OTULIN<sub>cat</sub>-Strep-tag II C129A</td>
                  <td>This paper</td>
                  <td>N/A</td>
                </tr>
                <tr>
                  <td>pASK-IBA3 OTULIN<sub>cat</sub>-Strep-tag II W96A</td>
                  <td>This paper</td>
                  <td>N/A</td>
                </tr>
                <tr>
                  <td>pASK-IBA3 His<sub>10</sub>-Ub-Ub</td>
                  <td>This paper</td>
                  <td>N/A</td>
                </tr>
                <tr>
                  <td>pASK-IBA3 His<sub>10</sub>-UbG76A-Ub</td>
                  <td>This paper</td>
                  <td>N/A</td>
                </tr>
                <tr>
                  <td>pASK-IBA3 His<sub>10</sub>-UbG76C-UbÎG76</td>
                  <td>This paper</td>
                  <td>N/A</td>
                </tr>
                <tr>
                  <td>pEF FLAG mock</td>
                  <td>Laboratory of Daniel Krappmann</td>
                  <td>(<xref rid="bib48" ref-type="bibr">Scharschmidt etÂ al., 2004</xref>)</td>
                </tr>
                <tr>
                  <td>pEF FLAG-OTULIN WT</td>
                  <td>This paper</td>
                  <td>N/A</td>
                </tr>
                <tr>
                  <td>pEF FLAG-OTULIN C129A</td>
                  <td>This paper</td>
                  <td>N/A</td>
                </tr>
                <tr>
                  <td>pcDNA3.1 (+)</td>
                  <td>Laboratory of Daniel Krappmann</td>
                  <td>(<xref rid="bib39" ref-type="bibr">Muller-Rischart etÂ al., 2013</xref>)</td>
                </tr>
                <tr>
                  <td>pcDNA3.1 HOIP-HA</td>
                  <td>Laboratory of Daniel Krappmann</td>
                  <td>(<xref rid="bib39" ref-type="bibr">Muller-Rischart etÂ al., 2013</xref>)</td>
                </tr>
                <tr>
                  <td>pcDNA3.1 HOIL-1-HA</td>
                  <td>Laboratory of Daniel Krappmann</td>
                  <td>(<xref rid="bib39" ref-type="bibr">Muller-Rischart etÂ al., 2013</xref>)</td>
                </tr>
                <tr>
                  <td>pcDNA3.1 HA-SHARPIN</td>
                  <td>Laboratory of Daniel Krappmann</td>
                  <td>(<xref rid="bib39" ref-type="bibr">Muller-Rischart etÂ al., 2013</xref>)</td>
                </tr>
                <tr>
                  <td>pEF FLAG-OTUB1</td>
                  <td>Laboratory of Kamyar Hadian</td>
                  <td>N/A</td>
                </tr>
                <tr>
                  <td>pEF FLAG-CYLD</td>
                  <td>Laboratory of Daniel Krappmann</td>
                  <td>N/A</td>
                </tr>
                <tr>
                  <td>pEF FLAG-A20</td>
                  <td>Laboratory of Daniel Krappmann</td>
                  <td>(<xref rid="bib9" ref-type="bibr">Duwel etÂ al., 2009</xref>)</td>
                </tr>
                <tr>
                  <td>pEF FLAG-YOD1</td>
                  <td>Laboratory of Daniel Krappmann</td>
                  <td>(<xref rid="bib49" ref-type="bibr">Schimmack etÂ al., 2017</xref>)</td>
                </tr>
                <tr>
                  <td>pEF4 FLAG-UCHL3</td>
                  <td>Laboratory of Daniel Krappmann</td>
                  <td>N/A</td>
                </tr>
                <tr>
                  <td colspan="3">
                    <hr/>
                  </td>
                </tr>
                <tr>
                  <td colspan="3">
                    <bold>Software and Algorithms</bold>
                  </td>
                </tr>
                <tr>
                  <td colspan="3">
                    <hr/>
                  </td>
                </tr>
                <tr>
                  <td>xia2</td>
                  <td>(<xref rid="bib57" ref-type="bibr">Winter etÂ al., 2013</xref>)</td>
                  <td>
                    <ext-link ext-link-type="uri" xlink:href="http://www.ccp4.ac.uk/" id="intref0100">http://www.ccp4.ac.uk/</ext-link>
                  </td>
                </tr>
                <tr>
                  <td>AIMLESS</td>
                  <td>(<xref rid="bib16" ref-type="bibr">Evans and Murshudov, 2013</xref>)</td>
                  <td>
                    <ext-link ext-link-type="uri" xlink:href="http://www.ccp4.ac.uk/" id="intref0105">http://www.ccp4.ac.uk/</ext-link>
                  </td>
                </tr>
                <tr>
                  <td>Phaser</td>
                  <td>(<xref rid="bib34" ref-type="bibr">McCoy, 2007</xref>)</td>
                  <td>
                    <ext-link ext-link-type="uri" xlink:href="http://www.ccp4.ac.uk/" id="intref0110">http://www.ccp4.ac.uk/</ext-link>
                  </td>
                </tr>
                <tr>
                  <td>COOT</td>
                  <td>(<xref rid="bib15" ref-type="bibr">Emsley etÂ al., 2010</xref>)</td>
                  <td>
                    <ext-link ext-link-type="uri" xlink:href="http://www.ccp4.ac.uk/" id="intref0115">http://www.ccp4.ac.uk/</ext-link>
                  </td>
                </tr>
                <tr>
                  <td>Refmac5</td>
                  <td>(<xref rid="bib40" ref-type="bibr">Murshudov etÂ al., 2011</xref>)</td>
                  <td>
                    <ext-link ext-link-type="uri" xlink:href="http://www.ccp4.ac.uk/" id="intref0120">http://www.ccp4.ac.uk/</ext-link>
                  </td>
                </tr>
                <tr>
                  <td>PyMOL</td>
                  <td>PyMOL</td>
                  <td>
                    <ext-link ext-link-type="uri" xlink:href="http://www.pymol.org" id="intref0125">http://www.pymol.org</ext-link>
                  </td>
                </tr>
                <tr>
                  <td>MaxQuant Software (version 1.5.2)</td>
                  <td/>
                  <td>
                    <ext-link ext-link-type="uri" xlink:href="http://www.coxdocs.org/doku.php?id=maxquant:start" id="intref0130">http://www.coxdocs.org/doku.php?id=maxquant:start</ext-link>
                  </td>
                </tr>
                <tr>
                  <td>Perseus Software (version 1.5.5.3)</td>
                  <td/>
                  <td>
                    <ext-link ext-link-type="uri" xlink:href="http://www.coxdocs.org/doku.php?id=perseus:start" id="intref0135">http://www.coxdocs.org/doku.php?id=perseus:start</ext-link>
                  </td>
                </tr>
                <tr>
                  <td>ImageJ</td>
                  <td>NIH</td>
                  <td>
                    <ext-link ext-link-type="uri" xlink:href="https://imagej.nih.gov/ij/" id="intref0140">https://imagej.nih.gov/ij/</ext-link>
                  </td>
                </tr>
                <tr>
                  <td colspan="3">
                    <hr/>
                  </td>
                </tr>
                <tr>
                  <td colspan="3">
                    <bold>Other</bold>
                  </td>
                </tr>
                <tr>
                  <td colspan="3">
                    <hr/>
                  </td>
                </tr>
                <tr>
                  <td>DMEM (high glucose, L-glutamine)</td>
                  <td>Life Technologies</td>
                  <td>Cat#11965092</td>
                </tr>
                <tr>
                  <td>RPMI 1640 Medium (L-glutamine)</td>
                  <td>Life Technologies</td>
                  <td>Cat#21875034</td>
                </tr>
                <tr>
                  <td>SOLA HRP SPE Cartridge</td>
                  <td>Thermo Scientific</td>
                  <td>Cat#60109-001</td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
        </p>
      </sec>
      <sec id="sec5.2">
        <title>Contact for Reagent and Resource Sharing</title>
        <p>Further information and requests for resources and reagents should be directed to and will be fulfilled by the corresponding authors, Farid El Oualid (<ext-link ext-link-type="uri" xlink:href="mailto:farideloualid@ubiqbio.com" id="intref0145">farideloualid@ubiqbio.com</ext-link>) and Daniel Krappmann (<ext-link ext-link-type="uri" xlink:href="mailto:daniel.krappmann@helmholtz-muenchen.de" id="intref0150">daniel.krappmann@helmholtz-muenchen.de</ext-link>).</p>
      </sec>
      <sec id="sec5.3">
        <title>Experimental Model and Subject Details</title>
        <sec id="sec5.3.1">
          <title>Cell Lines</title>
          <p>All mammalian cell lines were maintained at 37Â°C in a humidified atmosphere at 5% CO<sub>2</sub>. Jurkat TÂ cells were cultured in RPMI 1640 Medium, HEK293 cells in DMEM. Media were supplemented with 10% fetal calf serum, 100Â U/ml penicillin and 100Â Î¼g/ml streptomycin. Jurkat TÂ cells were authenticated by the Authentication Service of the Leibniz Institute DSMZ.</p>
        </sec>
      </sec>
      <sec id="sec5.4">
        <title>Method Details</title>
        <sec id="sec5.4.1">
          <title>Constructs</title>
          <p>DNA constructs for this study were generated by common molecular biological techniques using TOP10 Chemically Competent <italic>E.Â Coli</italic>. For bacterial expression of recombinant proteins, cDNAs were cloned into the pASK-IBA3(+) vector (IBA). For mammalian expression, cDNAs were cloned into a modified pEF4 (<xref rid="bib48" ref-type="bibr">Scharschmidt etÂ al., 2004</xref>) or the pcDNA3.1(+) backbone (Invitrogen). Mutations were introduced by site-directed mutagenesis.</p>
        </sec>
        <sec id="sec5.4.2">
          <title>Biotin-Ub<sub>G76Dha</sub>-Ub Synthesis</title>
          <p>LC-MS analysis was performed on a system equipped with a Waters 2795 separation Module (Alliance HT), Waters 2996 Photodiode Array Detector (190-700Â nm) and a Micromass LCT-TOF Premier mass spectrometer. Samples were run over an XBridge BEH300 C18 column (5Â Î¼m, 4.6 x 100Â mm, TÂ = 40Â°C) using a gradient of 30Â â 60% B (over 3.5Â min or 6Â min). Samples were run at 0.8Â mL/min using a gradient of two mobile phases: AÂ = 1% acetonitrile and 0.1% formic acid in water; BÂ = 1% water and 0.1% formic acid in acetonitrile. Preparative HPLC was performed on a Waters XBridgeâ¢ Prep C18 column (30 x 250Â mm, 5Î¼m OBDâ¢). Samples were run at 25Â ml/min using a gradient of two mobile phases: AÂ = 5% acetonitrile and 0.05% trifluoroacetic acid in water; BÂ = 5% water and 0.05% trifluoroacetic acid in acetonitrile. Gradient: 0 â 6Â min: 5 â 10% B; 6 â 10Â min: 10 â 30% B; 10 â 26Â min: 30Â âÂ 50% B; 26 â 27Â min: 50 â 95% B. Data processing was performed using Waters MassLynx 4.1 software.</p>
          <sec id="sec5.4.2.1">
            <title>Cys-Ub</title>
            <p>Full-length ubiquitin was synthesized by solid-phase peptide synthesis on Fmoc-Gly-TentaGel Trt R resin (0.18Â mmol/g) as reported earlier (<xref rid="bib12" ref-type="bibr">El Oualid etÂ al., 2010</xref>). The resin bound Ub (25Â Î¼mol) was washed with dichloromethane (DCM) in a 20Â ml syringe with a frit. Next, a solution of Fmoc-Cys(Trt)-OH (100Â Î¼mol, 58Â mg) and pyBOP (125Â Î¼mol, 65Â mg) in 5Â ml <italic>N</italic>-methyl-2-pyrollidone (NMP) was added followed by <italic>N,N</italic>-diisopropylethylamine (DiPEA) (250Â Î¼mol, 43Â Î¼L). The mixture was mixed overnight and the resin washed with NMP and DCM. The Fmoc-Cys(Trt)-OH coupling step was repeated but this time for 1 h. After washing, the resin was treated with 10Â ml of 20% piperidine in NMP for 10Â min, followed by a wash with NMP and DCM. This deprotection step was repeated twice. The resin was mixed with 5Â ml trifluoroacetic acid (TFA)/H<sub>2</sub>O/iPr<sub>3</sub>SiH/Phenol (90/5/2Â½/2Â½) for 3Â h after which the TFA solution was added to 45Â ml of cold diethyl ether:n-pentane 3:1 to precipitate the protein. The solution was centrifuged at 2000Â rpm for 10Â min (with slow brake), the diethyl ether:n-pentane decanted and 50Â ml diethyl ether were added to the protein pellet. The mixture was centrifuged at 2000Â rpm for 10Â min (with slow brake) and after decanting the diethyl ether layer, the diethyl ether wash step was repeated. Next, the pellet was dissolved in 15Â ml dimethylsulfoxide (DMSO), added to 40Â ml water and purified by RP-HPLC. Lyophilization of pooled fractions afforded 46Â mg of Cys-Ub as a white powder (5.3Â Î¼mol, 20%).</p>
          </sec>
          <sec id="sec5.4.2.2">
            <title>Biotin-Ahx-Ub(1-75)-SCH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>Me</title>
            <p>Ubiquitin(1-75) was synthesized by solid-phase peptide synthesis on Fmoc-Gly-TentaGel Trt R resin (0.18Â mmol/g) as reported earlier (<xref rid="bib12" ref-type="bibr">El Oualid etÂ al., 2010</xref>). The resin bound Ub(1-75) (40Â Î¼mol) was washed with DCM in a 20Â ml syringe with a frit. Next, a solution of Fmoc-aminohexanoic acid (200Â Î¼mol, 71Â mg), PyBOP (200Â Î¼mol, 104Â mg) and DiPEA (400Â Î¼mol, 70Â Î¼l) in 10Â ml NMP was added. The syringe was sealed and the mixture mixed overnight. After washing with NMP and DCM, the Fmoc-aminohexanoic acid coupling step was repeated for 1 h. After washing with NMP and DCM, the resin was mixed with 20Â ml of 20% piperidine in NMP for 10Â min, followed by a wash with NMP and DCM. This deprotection step was repeated twice. After washing the resin with NMP and DCM, the resin was treated with <italic>O</italic>-(Benzotriazol-1-yl)-<italic>N,N,Nâ²,Nâ²</italic>-tetramethyluronium hexafluorophosphate (HBTU), D-biotin (biotin), 1-hydroxybenzotriazole (HOBt) and DiPEA. For a good dissolution of biotin, the HBTU (200Â Î¼mol, 76Â mg) and HOBt (200Â Î¼mol, 31Â mg) were first dissolved in 10Â ml <italic>N,N</italic>-dimethylformamide (DMF), followed by the addition of biotin (200Â Î¼mol, 50Â mg) and DiPEA (400Â Î¼mol, 70Â Î¼l). The syringe was sealed and the mixture mixed overnight. After washing with NMP and DCM, the biotin coupling step was repeated for 1 h. After washing with NMP and DCM, the biotin-Ahx-Ub(1-75) was cleaved selectively from the TentaGel Trt R resin by mixing in 30Â ml of 4:1 DCM/1,1,1,3,3,3-hexafluoroisopropanol (HFIP) for 45Â min. The resin was flushed 3Ã with 10Â ml DCM and treated again with 30Â ml of 4:1 DCM/HFIP for 30Â min. The combined 4:1 DCM/HFIP solution was concentrated, co-evaporated 3Ã with DCM and dried using high vacuum. Next, the globally protected biotin-Ahx-Ub(1-75) was dissolved in 15Â ml DCM and treated overnight with PyBOP (200Â Î¼mol, 76Â mg), methyl 3-mercaptopropionate (200Â Î¼mol, 23Â Î¼l) and DiPEA (400Â Î¼mol, 70Â Î¼l). The DCM was evaporated and treated for 3Â h with 10Â ml of TFA/H<sub>2</sub>O/iPr<sub>3</sub>SiH/phenol (90/5/2.5/2.5 vol%). The TFA solution was added to 90Â ml of cold 1:3 pentane:ether (reaction flask rinsed with 2Â ml of TFA) to precipitate the protein (solution divided over two 50Â ml falcon tubes). The solution was centrifuged at 2000Â rpm for 10Â min (with slow brake), the diethyl ether:n-pentane decanted and 100Â ml diethyl ether were added to the protein pellet. The mixture was centrifuged at 2000Â rpm for 10Â min (with slow brake) and after decanting the ether layer, the ether wash step was repeated. The pellet was dissolved in 5Â ml DMSO, added to 40Â ml water and purified by RP-HPLC. Lyophilization of pooled fractions afforded 150Â mg of biotin-Ahx-Ub(1-75)-SCH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>Me as a white powder (16.7Â Î¼mol, 42%).</p>
          </sec>
          <sec id="sec5.4.2.3">
            <title>Biotin-Ahx-Ub(1-75)-Cys-Ub</title>
            <p>Cys-Ub (26Â mg, 3.0Â Î¼mol) and Biotin-Ahx-Ub(1-75)-S(CH<sub>2</sub>)<sub>2</sub>CO<sub>2</sub>Me (30Â mg, 3.3Â Î¼mol) were dissolved in 1Â ml ligation buffer: 6M Gdn-HCl, 0.15Â M NaP, 100Â mM 4-mercaptophenylacetic acid (MPAA), pH 7.4 and incubated overnight at 37Â°C. After LC-MS analysis showing complete consumption of Cys-Ub, the reaction mixture was diluted to 20Â ml with 6M Gdn-HCl, 0.15Â M NaP pH 7.4 and treated with 20Â mM TCEP for 30Â min to reduce any disulfides. Purification by RP-HPLC and lyophilization of pooled fractions afforded 30Â mg of biotin-Ahx-Ub(1-75)-Cys-Ub (1.7Â Î¼mol, 57%) as a white powder.</p>
          </sec>
          <sec id="sec5.4.2.4">
            <title>Biotin-Ahx-Ub(1-75)-Dha-Ub</title>
            <p>Biotin-Ahx-Ub(1-75)-Cys-Ub (30Â mg, 1.7Â Î¼mol) was dissolved in DMSO (40Â mg/ml, 0.75Â ml) and diluted with 12Â ml milliQ. Next, this was buffered with 3Â ml of 500Â mM sodium phosphate buffer pH 8.1 to 100Â mM sodium phosphate. A solution of 6Â mg <italic>O</italic>-mesitylenesulfonylhydroxylamine (MSH, 15 eq) (<xref rid="bib2" ref-type="bibr">Bernardes etÂ al., 2008</xref>, <xref rid="bib38" ref-type="bibr">Mulder etÂ al., 2014</xref>) in 50Â Î¼L DMF was added. After overnight incubation at 40Â°C, LC-MS analysis confirmed completion. Purification by RP-HPLC and lyophilization of pooled fractions afforded 21Â mg biotin-Ahx-Ub(1-75)-Dha-Ub (bio-Ub<sub>G76Dha</sub>-Ub, 1.2Â Î¼mol, 71%) (<xref rid="mmc1" ref-type="supplementary-material">FigureÂ S1</xref>).</p>
            <p>For experimental applications, the probe was first dissolved to 40Â mg/ml in DMSO and this was diluted to 1Â mg/ml (57Â Î¼M) in 50Â mM Tris (pH 7.5) and 100Â mM NaCl (final DMSO concentration is 2.5 vol%).</p>
          </sec>
        </sec>
        <sec id="sec5.4.3">
          <title>His<sub>10</sub>-Ub<sub>G76Dha</sub>-Ub<sub>ÎG76</sub> Synthesis</title>
          <p>In contrast to the OTULIN ABP synthesis, the synthesis of the His<sub>10</sub>-Ub<sub>G76Dha</sub>-Ub<sub>ÎG76</sub> (OTULIN ABPÎG76) was not based on solid-phase peptide synthesis, but on a recombinant precursor protein. This His<sub>10</sub>-Ub<sub>G76C</sub>-Ub<sub>ÎG76</sub>, which carries a G76C substitution in the distal ubiquitin and lacks the C-terminal glycine of the proximal ubiquitin, was produced in <italic>E.Â coli</italic> BL21-CodonPlus (DE3)-RIPL cells and purified as described below. To a solution of His<sub>10</sub>-Ub<sub>G76C</sub>-Ub<sub>ÎG76</sub> (9Â ml, 0.15Â mg/ml, 1.35Â mg) in 100Â mM sodium phosphate pHÂ 8 was added a solution of 0.3Â mg <italic>O</italic>-mesitylenesulfonylhydroxylamine (MSH, 15 eq) (<xref rid="bib2" ref-type="bibr">Bernardes etÂ al., 2008</xref>, <xref rid="bib38" ref-type="bibr">Mulder etÂ al., 2014</xref>) in 50Â Î¼l DMF. After overnight incubation at 40Â°C, LC-MS analysis showed completion (<xref rid="mmc1" ref-type="supplementary-material">FigureÂ S4</xref>G). For experimental applications, the probe was not further purified and stored in the present buffer (0.15Â mg/ml).</p>
        </sec>
        <sec id="sec5.4.4">
          <title>Production and Purification of Recombinant Proteins</title>
          <p>C-terminally Strep-tag II (ST)-tagged OTULIN constructs and N-terminally His<sub>10</sub>-tagged diUb variants were expressed in <italic>E.Â coli</italic> BL21-CodonPlus (DE3)-RIPL cells and purified via affinity chromatography using the ÃKTA Purifier system (GE Healthcare). Bacteria were grown at 37Â°C in LB medium containing 100Â Î¼g/ml ampicillin and 25Â Î¼g/ml chloramphenicol to an OD<sub>600</sub> of 0.6-0.8 before induction with 0.5Â mM IPTG and 200Â ng/ml anhydrotetracycline. Proteins were produced overnight at 21Â°C. Harvested cultures were lysed by sonification in lysis buffer (100Â mM Tris pH 8.0, 150Â mM NaCl, 1Â mM EDTA, 0.5Â mg/ml lysozyme, and protease inhibitor cocktail for ST-tagged constructs or 100Â mM Tris pH 8.0, 150Â mM NaCl, 30Â mM imidazole, 0.5Â mg/ml lysozyme, and protease inhibitor cocktail for His<sub>10</sub>-tagged constructs). Cleared lysates containing ST-tagged proteins were applied on StrepTrap columns (GE Healthcare) and unspecifically binding proteins were washed away with washing buffer (100Â mM Tris pH 8.0, 150Â mM NaCl,Â 1Â mM EDTA). Constructs were eluted using elution buffer (100Â mM Tris pH 8.0, 150Â mM NaCl, 1Â mM EDTA, 2.5Â mM D-desthiobiotin) and desalted via HiTrap Desalting columns (GE Healthcare) in 20Â mM Tris pH 8, 100Â mM NaCl. Cleared lysates containing His<sub>10</sub>-tagged diUb variants were applied on HisTrap columns (GE Healthcare) and unspecific proteins were washed away with washing buffer (100Â mM Tris pH 8.0, 150Â mM NaCl, 30Â mM imidazole). diUb constructs were eluted by a gradient of elution bufferÂ (100Â mM Tris pH 8.0, 150Â mM NaCl, 300Â mM imidazole) and desalted via HiTrap Desalting columns in sodium phosphate bufferÂ pH 8.</p>
        </sec>
        <sec id="sec5.4.5">
          <title>Analytical Size Exclusion Chromatography</title>
          <p>Analytical size exclusion chromatography was performed on an AKTA Micro System (GE Life Sciences) using a Superdex 75 PC 3.2/30 column equilibrated in: 20Â mM Tris pH 7.4, 150Â mM NaCl, 2Â mM DTT. In total 25Â Î¼l of 80Â Î¼M of each sample was loaded onto the column. Complexes were mixed at an equimolar ratio and incubated at room temperature for 10Â min prior to loading onto the column. Fractions containing proteins were mixed with SDS sample loading buffer and subjected to SDS-PAGE analysis.</p>
        </sec>
        <sec id="sec5.4.6">
          <title>Labeling Recombinant DUBs with OTULIN ABP or Ub-PA</title>
          <p>Recombinant DUBs were diluted in reaction buffer (50Â mM Tris, 5Â mM DTT,Â +/- 0.03% BSA) and incubated for the indicated times at 30Â°C or 37Â°C with different amounts of OTULIN ABP or biotin-Ahx-Ub-PA (amounts specified in FigureÂ Legends). Reactions were stopped by boiling after addition of reducing SDS sample buffer and proteins were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). DUB-diUb or DUB-Ub complex formation was analyzed by Coomassie staining, or Silver staining using the Pierce Silver Stain Kit according to the manufacturer's instructions.</p>
          <p>To analyze the reactivity of OTULIN (aa 1-352) and CYLD (aa 583-956), 15Â Î¼M of each enzyme was mixed with an equimolar amount of either Ub-PA or bio-Ub<sub>G76Dha</sub>-Ub and incubated at RT for 30Â min. SDS sample buffer was used to quench the reaction and samples were resolved by SDS-PAGE analysis and stained with Coomassie.</p>
        </sec>
        <sec id="sec5.4.7">
          <title>Ubiquitin Chain Cleavage Assay</title>
          <p>OTULIN<sub>cat</sub> WT (500 pM) was diluted in reaction buffer (50Â mM Tris, 5Â mM DTT and 0.03% BSA) and incubated at 37Â°C for 25Â min with 250Â ng of M1-linked tetraUb chains. For inhibition, OTULIN was treated with OTULIN ABP or PR-619 at the indicated concentrations (1h, RT), prior to addition of the tetraUb chains. In diUb cleavage assays, DUBs (500Â nM) were incubated in 50Â mM Tris and 5Â mM DTT with 500Â ng of diUb chains (either K48-linked, M1-linked or Ub<sub>G76A</sub>-Ub mutant) for 1Â h at 30Â°C. Cleavage reactions were stopped by boiling in 1x SDS sample buffer and analyzed by Western Blot or Silver staining.</p>
        </sec>
        <sec id="sec5.4.8">
          <title>Crystallization</title>
          <p>The expression and purification of OTULIN (80-352) for crystallography has been described previously (<xref rid="bib26" ref-type="bibr">Keusekotten etÂ al., 2013</xref>). Purified OTULIN was incubated with two molar excess of bio-Ub<sub>G76Dha</sub>-Ub (OTULIN-ABP) for 1Â h at 30Â°C. Unreacted bio-Ub<sub>G76Dha</sub>-Ub and OTULIN were resolved from OTULIN-diUb by anion exchange chromatography (ResourceQ; GE Healthcare) in 20Â mM Tris pH 8.5, 4Â mM DTT. OTULIN-diUb was further purified by size exclusion chromatography (Hiload 16/60 Superdex 75; GE Healthcare) in buffer containing 20Â mM Tris pH 7.4, 150Â mM NaCl, 4Â mM DTT. Crystals of OTULIN-diUb were grown by sitting drop vapour diffusion around conditions that yielded the previously published OTULIN (C129A) Met1 diUb structure (1.9-2.1Â M ammonium sulfate, 100Â mM bis-tris pH 6.3-6.6) (<xref rid="bib26" ref-type="bibr">Keusekotten etÂ al., 2013</xref>). Small crystals of â¼50Â Î¼m grew within 14Â days and were transferred into 3.4Â M sodium malonate pH 7.0 prior to cryo-cooling.</p>
          <p>Structure determination and refinement diffraction data were collected at Diamond Light source beamline I04. Owing to the small size of the crystals, only diffraction data to 3Â Ã could be collected.</p>
        </sec>
        <sec id="sec5.4.9">
          <title>Structure Determination and Refinement of Crystal Structure</title>
          <p>Diffraction images were processed using xia2 (<xref rid="bib57" ref-type="bibr">Winter etÂ al., 2013</xref>) and scaled using AIMLESS (<xref rid="bib16" ref-type="bibr">Evans and Murshudov, 2013</xref>). The cell dimensions were very similar between the OTULIN-diUb and OTULIN (C129A) Met1 diUb datasets (a=b=101.14, c= 277.92 versus a=b=100.02, c=280.26 respectively). However, the OTULIN-diUb structure converged more satisfactorily during refinement once Met1 diUb, lacking Gly75-Met1 had been placed separately to OTULIN in molecular replacement using Phaser (<xref rid="bib34" ref-type="bibr">McCoy, 2007</xref>). Model building and refinement were performed with COOT (<xref rid="bib15" ref-type="bibr">Emsley etÂ al., 2010</xref>) and Refmac5 (<xref rid="bib40" ref-type="bibr">Murshudov etÂ al., 2011</xref>), respectively. Owing to the lower resolution of the OTULIN-diUb complex external restraints were applied from the higher resolution OTULIN (C129A) Met1Â diUb structure in the early stages of refinement using PROSMART followed by separate JellyBody refinement according to (<xref rid="bib31" ref-type="bibr">Kovalevskiy etÂ al., 2016</xref>) using Refmac5 (<xref rid="bib40" ref-type="bibr">Murshudov etÂ al., 2011</xref>). Continuous electron density could be observed for the missing dehydroalanine, which was placed with restraints generated by JLigand. Final stages of refinement included TLS parameters defined separately for OTULIN and diUb. Data collection and refinement statistics can be found in <xref rid="mmc1" ref-type="supplementary-material">Table S1</xref>. All structure figures were generated with Pymol (<ext-link ext-link-type="uri" xlink:href="http://www.pymol.org" id="intref0155">www.pymol.org</ext-link>).</p>
        </sec>
        <sec id="sec5.4.10">
          <title>Stimulation and Transfection of Cells</title>
          <p>Cells were stimulated by treating them with 20Â ng/ml recombinant human TNFÎ± for 0 â 90Â min. For transient overexpression of proteins, HEK293 cells were transfected using standard calcium phosphate transfection protocols.</p>
        </sec>
        <sec id="sec5.4.11">
          <title>Treatment of Cell Extracts with diUb Probes</title>
          <p>For the treatment of cell extracts with diUb probes, 2 â 3x10<sup>6</sup> HEK293 or Jurkat TÂ cells were lysed in 250Â Î¼l co-IP buffer (25Â mM HEPES pH 7.5, 150Â mM NaCl, 0.2% NP-40, 10% glycerol, 1Â mM DTT, 10Â mM sodium fluoride, 8Â mM Î²-glycerophosphate and 300Â Î¼M sodium vanadate) without protease inhibitors. Lysates were divided into aliquots (20 â 50Â Î¼l reaction volume / sample). To analyze labeling of cellular DUBs or the formation of polyUb chains, different amounts of OTULIN ABP, OTULIN ABPÎG76 or Ub<sub>G76A</sub>-Ub were added to the samples and incubated at 30 or 37Â°C for 2 â 60Â min (indicated in FigureÂ Legends). Reactions were stopped by boiling in reducing sample buffer and analyzed by Western Blot. For ATP depletion, aliquots were treated with 0.5Â U Apyrase for 30Â min before the addition of OTULIN ABP. For linkage analyses of enriched polyUb chains, 44Â Î¼l aliquots were treated first with 1Â Î¼g OTULIN-ABP for 30Â min at 37Â°C before adding 5Â Î¼l of different linkage-specific 10x DUBs (from the UbiCREST Deubiquitinase Enzyme Set) and incubating for further 30Â min at 37Â°C.</p>
        </sec>
        <sec id="sec5.4.12">
          <title>Pull-down (PD) Experiments</title>
          <sec id="sec5.4.12.1">
            <title>ST-PDs</title>
            <p>For Strep-tag II(ST)-PDs, 20Â Î¼g of recombinant OTULIN<sub>cat</sub>-ST (WT, C129A) were mixed with equimolar amounts of His<sub>10</sub>-Ub-Ub WT or His<sub>10</sub>-Ub<sub>G76A</sub>-Ub in buffer A (PBS, 0.1% BSA, 5% glycerol, 0.1% Triton-X and protease inhibitors, total volume 500Â Î¼l) and incubated on the turning wheel for 2Â h at 4Â°C. 20Â Î¼l were removed from each sample as Input controls (INPUT). Strep-Tactin Sepharose was pre-equilibrated in buffer A, added to the samples (60Â Î¼l of 50% slurry / sample) and incubated for 1Â h with the protein mixtures to enable binding of OTULIN<sub>cat</sub>-ST to the resin. The resin was pelleted by centrifugation (2500<italic>g</italic> / 4Â°C / 1Â min) and another control sample was removed from each supernatant to check whether proteins had been depleted from the solution by the pull-down procedure. OTULIN-coupled resin was washed eight times with buffer B (PBS, 0.1% BSA, 5% glycerol, 0.5% Triton-X and protease inhibitors) to get rid of loose protein interactions and subsequently boiled in 25Â Î¼l of 2x reducing SDS sample buffer. Control samples were denatured by boiling in 1x SDS sample buffer and could be analyzed together with the pull-down eluates by Western Blot after SDS-PAGE.</p>
          </sec>
          <sec id="sec5.4.12.2">
            <title>His-PDs / OTULIN ABPÎG76-PDs</title>
            <p>For His-PDs, 2x10<sup>7</sup> Jurkat TÂ cells were lysed in lysis buffer (150Â mM NaCl, 50Â mM NaH<sub>2</sub>PO<sub>4</sub>, 0.2% NP-40, 10% glycerol, 10Â mM imidazole, 1Â mM DTT, 10Â mM sodium fluoride, 8Â mM Î²-glycerophosphate and 300Â Î¼M sodium vanadate, pH 8) without protease inhibitors for 20Â min at 4Â°C. Cell debris was removed from the lysate by centrifugation (20,000<italic>g</italic>, 10Â min, 4Â°C). To check if equal cell numbers were used, 30Â Î¼l was removed from each sample (INPUT/lysate). Cell extracts were then incubated with 4Â Î¼g His<sub>10</sub>-Ub<sub>G76Dha</sub>-Ub<sub>ÎG76</sub> (OTULIN ABPÎG76) for 60Â min at RT, enabling the coupling of active OTULIN and the probe. Ni-NTA Agarose was pre-equilibrated in lysis buffer, added to the samples (35Â Î¼l of 50% slurry per sample) and incubated on the turning wheel for 2Â h at 4Â°C. By centrifugation (500<italic>g</italic> / 2Â min / 4Â°C) beads were sedimented and subsequently washed 3 times with 1Â ml of washing buffer (300Â mM NaCl, 50Â mM NaH<sub>2</sub>PO<sub>4</sub>, 0.2% NP-40, 10% glycerol, 20Â mM imidazole, pH 8) to get rid of unspecifically binding proteins. OTULIN ABPÎG76-bound protein complexes were eluted by boiling the beads in 2x reducing SDS sample buffer (25Â Î¼l) and analyzed by Western Blot after SDS-PAGE.</p>
          </sec>
          <sec id="sec5.4.12.3">
            <title>Biotin / OTULIN ABP-PDs</title>
            <p>For Biotin-PDs, 1x10<sup>7</sup> HEK293 or 2x10<sup>7</sup> Jurkat TÂ cells were lysed in 500Â Î¼l co-IP buffer (25Â mM HEPES pH 7.5, 150Â mM NaCl, 0.2% NP-40, 10% glycerol, 1Â mM DTT, 10Â mM sodium fluoride, 8Â mM Î²-glycerophosphate and 300Â Î¼M sodium vanadate) without protease inhibitors for 20Â min at 4Â°C. Cell debris was removed from the lysate by centrifugation (20,000<italic>g</italic>, 10Â min, 4Â°C). To check if equal cell numbers were used, 30Â Î¼l was removed from each sample (INPUT/lysate). For a pre-clearing step, cell extracts were mixed with 15Â Î¼l of High Capacitiy Streptavidin Agarose and incubated on the turning wheel for 1Â h at 4Â°C. The beads were sedimented by centrifugation (2500<italic>g</italic> / 2Â min / 4Â°C) and 450Â Î¼l of the resulting supernatant were transferred into a new reaction tube. The pre-cleared cell extracts were then incubated at with 2 - 4Â Î¼g OTULIN ABP (15 â 60Â min), enabling the covalent coupling of active OTULIN and the probe. To bind and precipitate the formed OTULIN-diUb complexes, 25 â 35Â Î¼l of streptavidin agarose was added and incubated with the samples on the turning wheel for 1 - 2Â h at 4Â°C. After a first centrifugation step (2,500<italic>g</italic> / 4Â°C / 2Â min), control samples (30Â Î¼l) were removed from each supernatant to monitor depletion of proteins by the pull-down procedure. Then, beads were washed three times with 1Â ml co-IP buffer to get rid of unspecific interactions. Protein complexes were eluted by boiling beads in 25Â Î¼l 2x SDS sample buffer and analyzed by Western Blot after SDS-PAGE.</p>
            <p>To determine protein levels in input (prior to PD) and supernatant (after PD), control samples were denatured by boiling in SDS sample buffer and loaded in equal amounts on SDS gels for Western Blot Analysis. All protein band intensities were quantified using ImageJ software and normalized to Î²-actin. The ratio of quantified proteins between the supernatant and input was calculated to obtain relative amounts of âfreeâ OTULIN-diUb unbound proteins.</p>
            <p>To identify highly affine OTULIN ABP interactors by Mass Spectrometry Analysis, we used a larger quantity of cells (5x10<sup>7</sup> cells, lysed in 1Â ml co-IP buffer) for the biotin-PDs. Pre-cleared lysates (950Â Î¼l) were incubated for 30Â min at 30Â°C with (or without) Apyrase (4Â U), to deplete cellular ATP. To inhibit DUBs, samples were incubated for further 30Â min at 30Â°C with (or without) PR-619 (250Â Î¼M). Extracts were then treated with (or without) OTULIN ABP (5Â Î¼g) for 15Â min at RT before adding 35Â Î¼l streptavidin agarose to pull-down protein-ABP complexes (2h, 4Â°C). In order to get rid of most non-covalent ABP interactors, beads were washed twice with co-IP buffer and subsequently twice with high-stringent 1% SDS-containing co-IP buffer. PDs were eluted by boiling the beads in 50Â Î¼l 2x SDS sample buffer. 2.5Â Î¼l (5%) was removed for Western Blot analysis, whereas the rest was analyzed by LC-MS/MS.</p>
          </sec>
        </sec>
        <sec id="sec5.4.13">
          <title>Protein Digest for Mass Spectrometry Analysis</title>
          <p>PD eluates for LC-MS/MS analysis were diluted to 175Â Î¼l with ultra-pure water and reduced with 5Â Î¼l DTT (200Â mM in 0.1Â M Tris, pHÂ 7.8) for 30Â min at RT. Samples were alkylated with 20Â Î¼l iodoacetamide (200Â mM in 0.1Â M Tris, pH 7.8) for 30Â min at RT, followed by protein precipitation using a double methanol/chloroform extraction method (<xref rid="bib56" ref-type="bibr">Wessel and Flugge, 1984</xref>). Protein samples were treated with 600Â Î¼l Methanol, 150Â Î¼l chloroform and 450Â Î¼l water, followed by vigorous vortexing. Samples were centrifuged at 17,000<italic>g</italic> for 3Â min and the resultant upper aqueous phase was removed. Proteins were pelleted following addition of 450Â Î¼l water and centrifugation at 17,000<italic>g</italic> for 6Â min. The supernatant was removed, and the extraction process repeated. Following the second extraction process, precipitated proteins were re-suspended in 50Â Î¼l Urea (6M) and diluted toÂ &lt; 1M urea with 250Â Î¼l ultra-pure water. Protein digestion was carried out with 0.6Â Î¼g trypsin (3Â Î¼l; 20Â Î¼g in 100Â Î¼l Trypsin resuspension buffer) at 37Â°C overnight. Following digestion, samples were acidified with 1% formic acid and desalted on C18 solid-phase extraction cartridges (SOLA HRP C18 Cartridge), dried and re-suspended in 2% acetonitrile, 0.1% formic acid for analysis by LC-MS/MS.</p>
        </sec>
        <sec id="sec5.4.14">
          <title>Liquid Chromatography- Mass Spectrometry/Mass Spectrometry (LC-MS/MS)</title>
          <p>LC-MS/MS analysis was performed in biological quadruplicate using a Dionex Ultimate 3000 nano-ultra high pressure reverse phase chromatography coupled on-line to a Q Exactive High Field (HF) mass spectrometer (Thermo Scientific). Samples were separated on an EASY-Spray PepMap RSLC C18 column (500Â mm x 75Â Î¼m, 2Â Î¼m particle size, Thermo Scientific) over a 60Â minute gradient of 2-35% acetonitrile in 5% DMSO, 0.1% formic acid at 250 nl/min. MS1 scans were acquired at a resolution of 60,000 at 200 m/z and the top 12 most abundant precursor ions were selected for HCD fragmentation.</p>
        </sec>
        <sec id="sec5.4.15">
          <title>Mass Spectrometry DUB Profiling and Interactome Data Analysis</title>
          <p>From raw MS files, searches against the UniProtKB human sequence data base (retrieved 15.10.2014) and label-free quantitation were performed using MaxQuant Software (v1.5.2). Search parameters include carbamidomethyl (C) as a fixed modification, oxidation (M) and deamidation (NQ as variable modifications, maximum 2 missed cleavages, matching between runs, and LFQ quantitation was performed using unique peptides. Label-free interaction data analysis was performed using Perseus (v.1.5.5.3) and volcano plots were generated using FDR=0.01 and s0=2 as cutoff parameters.</p>
        </sec>
      </sec>
      <sec id="sec5.5">
        <title>Data and Software Availability</title>
        <p>The structure of the OTULIN-bio-Ub<sub>G76Dha</sub>-Ub complex has been deposited with the Protein Data Bank under the accession code PDB: <ext-link ext-link-type="uri" xlink:href="pdb:5OE7" id="intref0160">5OE7</ext-link>.</p>
        <p>The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (<xref rid="bib54" ref-type="bibr">Vizcaino etÂ al., 2016</xref>) partner repository with the dataset identifier <ext-link ext-link-type="uri" xlink:href="pride:PXD006868" id="intref0165">PXD006868</ext-link>.</p>
      </sec>
    </sec>
    <sec id="sec6">
      <title>Author Contributions</title>
      <p>A.W. conceived and performed most experiments, analyzed and interpreted the data, and helped to write the manuscript. P.E. and D.Ko. conceived and performed structural studies, contributed reagents, and provided expertise. A.P.F., S.B., and B.M.K. conceived, performed, and analyzed the MS experiments with material provided by A.W. F.E.O. designed and synthesized the bio-Ub<sub>G76Dha</sub>-Ub probe. D.K. conceived the study/experiments, wrote the manuscript and secured funding. All authors read, acknowledged, and helped with the final version of the manuscript.</p>
    </sec>
  </body>
  <back>
    <ref-list id="cebib0010">
      <title>References</title>
      <ref id="bib1">
        <element-citation publication-type="journal" id="sref1">
          <person-group person-group-type="author">
            <name>
              <surname>Altun</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kramer</surname>
              <given-names>H.B.</given-names>
            </name>
            <name>
              <surname>Willems</surname>
              <given-names>L.I.</given-names>
            </name>
            <name>
              <surname>McDermott</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Leach</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Goldenberg</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>K.G.</given-names>
            </name>
            <name>
              <surname>Konietzny</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Kogan</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes</article-title>
          <source>Chem. Biol.</source>
          <volume>18</volume>
          <year>2011</year>
          <fpage>1401</fpage>
          <lpage>1412</lpage>
          <pub-id pub-id-type="pmid">22118674</pub-id>
        </element-citation>
      </ref>
      <ref id="bib2">
        <element-citation publication-type="journal" id="sref2">
          <person-group person-group-type="author">
            <name>
              <surname>Bernardes</surname>
              <given-names>G.J.</given-names>
            </name>
            <name>
              <surname>Chalker</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Errey</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>B.G.</given-names>
            </name>
          </person-group>
          <article-title>Facile conversion of cysteine and alkyl cysteines to dehydroalanine on protein surfaces: versatile and switchable access to functionalized proteins</article-title>
          <source>J.Â Am. Chem. Soc.</source>
          <volume>130</volume>
          <year>2008</year>
          <fpage>5052</fpage>
          <lpage>5053</lpage>
          <pub-id pub-id-type="pmid">18357986</pub-id>
        </element-citation>
      </ref>
      <ref id="bib3">
        <element-citation publication-type="journal" id="sref3">
          <person-group person-group-type="author">
            <name>
              <surname>Bremm</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Freund</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Komander</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Lys11-linked ubiquitin chains adopt compact conformations and are preferentially hydrolyzed by the deubiquitinase Cezanne</article-title>
          <source>Nat. Struct. Mol. Biol.</source>
          <volume>17</volume>
          <year>2010</year>
          <fpage>939</fpage>
          <lpage>947</lpage>
          <pub-id pub-id-type="pmid">20622874</pub-id>
        </element-citation>
      </ref>
      <ref id="bib4">
        <element-citation publication-type="journal" id="sref4">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Ge</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>An ultrasensitive system for measuring the USPs and OTULIN activity using Nanoluc as a reporter</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <volume>455</volume>
          <year>2014</year>
          <fpage>178</fpage>
          <lpage>183</lpage>
          <pub-id pub-id-type="pmid">25449266</pub-id>
        </element-citation>
      </ref>
      <ref id="bib5">
        <element-citation publication-type="journal" id="sref5">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Pickart</surname>
              <given-names>C.M.</given-names>
            </name>
          </person-group>
          <article-title>A 25-kilodalton ubiquitin carrier protein (E2) catalyzes multi-ubiquitin chain synthesis via lysine 48 of ubiquitin</article-title>
          <source>J.Â Biol. Chem.</source>
          <volume>265</volume>
          <year>1990</year>
          <fpage>21835</fpage>
          <lpage>21842</lpage>
          <pub-id pub-id-type="pmid">2174887</pub-id>
        </element-citation>
      </ref>
      <ref id="bib6">
        <element-citation publication-type="journal" id="sref6">
          <person-group person-group-type="author">
            <name>
              <surname>Damgaard</surname>
              <given-names>R.B.</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Marco-Casanova</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Morgan</surname>
              <given-names>N.V.</given-names>
            </name>
            <name>
              <surname>Titheradge</surname>
              <given-names>H.L.</given-names>
            </name>
            <name>
              <surname>Elliott</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>McHale</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Maher</surname>
              <given-names>E.R.</given-names>
            </name>
            <name>
              <surname>McKenzie</surname>
              <given-names>A.N.</given-names>
            </name>
            <name>
              <surname>Komander</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>The deubiquitinase OTULIN is an essential negative regulator of inflammation and autoimmunity</article-title>
          <source>Cell</source>
          <volume>166</volume>
          <year>2016</year>
          <fpage>1215</fpage>
          <lpage>1230.e20</lpage>
          <pub-id pub-id-type="pmid">27523608</pub-id>
        </element-citation>
      </ref>
      <ref id="bib7">
        <element-citation publication-type="journal" id="sref7">
          <person-group person-group-type="author">
            <name>
              <surname>de Jong</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Merkx</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Berlin</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Rodenko</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Wijdeven</surname>
              <given-names>R.H.</given-names>
            </name>
            <name>
              <surname>El Atmioui</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Yalcin</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Robson</surname>
              <given-names>C.N.</given-names>
            </name>
            <name>
              <surname>Neefjes</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Ovaa</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Ubiquitin-based probes prepared by total synthesis to profile the activity of deubiquitinating enzymes</article-title>
          <source>ChemBioChem</source>
          <volume>13</volume>
          <year>2012</year>
          <fpage>2251</fpage>
          <lpage>2258</lpage>
          <pub-id pub-id-type="pmid">23011887</pub-id>
        </element-citation>
      </ref>
      <ref id="bib8">
        <element-citation publication-type="journal" id="sref8">
          <person-group person-group-type="author">
            <name>
              <surname>Draber</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Kupka</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Reichert</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Draberova</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Lafont</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>de Miguel</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Spilgies</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Surinova</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Taraborrelli</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Hartwig</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>LUBAC-recruited CYLD and A20 regulate gene activation and cell death by exerting opposing effects on linear ubiquitin in signaling complexes</article-title>
          <source>Cell Rep.</source>
          <volume>13</volume>
          <year>2015</year>
          <fpage>2258</fpage>
          <lpage>2272</lpage>
          <pub-id pub-id-type="pmid">26670046</pub-id>
        </element-citation>
      </ref>
      <ref id="bib9">
        <element-citation publication-type="journal" id="sref9">
          <person-group person-group-type="author">
            <name>
              <surname>Duwel</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Welteke</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Oeckinghaus</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Baens</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kloo</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Ferch</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Darnay</surname>
              <given-names>B.G.</given-names>
            </name>
            <name>
              <surname>Ruland</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Marynen</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Krappmann</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>A20 negatively regulates TÂ cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains</article-title>
          <source>J.Â Immunol.</source>
          <volume>182</volume>
          <year>2009</year>
          <fpage>7718</fpage>
          <lpage>7728</lpage>
          <pub-id pub-id-type="pmid">19494296</pub-id>
        </element-citation>
      </ref>
      <ref id="bib10">
        <element-citation publication-type="journal" id="sref10">
          <person-group person-group-type="author">
            <name>
              <surname>Ekkebus</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Flierman</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Geurink</surname>
              <given-names>P.P.</given-names>
            </name>
            <name>
              <surname>Ovaa</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Catching a DUB in the act: novel ubiquitin-based active site directed probes</article-title>
          <source>Curr. Opin. Chem. Biol.</source>
          <volume>23</volume>
          <year>2014</year>
          <fpage>63</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="pmid">25461387</pub-id>
        </element-citation>
      </ref>
      <ref id="bib11">
        <element-citation publication-type="journal" id="sref11">
          <person-group person-group-type="author">
            <name>
              <surname>Ekkebus</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>van Kasteren</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>Kulathu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Scholten</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Berlin</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Geurink</surname>
              <given-names>P.P.</given-names>
            </name>
            <name>
              <surname>de Jong</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Goerdayal</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Neefjes</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Heck</surname>
              <given-names>A.J.</given-names>
            </name>
          </person-group>
          <article-title>On terminal alkynes that can react with active-site cysteine nucleophiles in proteases</article-title>
          <source>J.Â Am. Chem. Soc.</source>
          <volume>135</volume>
          <year>2013</year>
          <fpage>2867</fpage>
          <lpage>2870</lpage>
          <pub-id pub-id-type="pmid">23387960</pub-id>
        </element-citation>
      </ref>
      <ref id="bib12">
        <element-citation publication-type="journal" id="sref12">
          <person-group person-group-type="author">
            <name>
              <surname>El Oualid</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Merkx</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Ekkebus</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Hameed</surname>
              <given-names>D.S.</given-names>
            </name>
            <name>
              <surname>Smit</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>de Jong</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Hilkmann</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Sixma</surname>
              <given-names>T.K.</given-names>
            </name>
            <name>
              <surname>Ovaa</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Chemical synthesis of ubiquitin, ubiquitin-based probes, and diubiquitin</article-title>
          <source>Angew. Chem. Int. Ed.</source>
          <volume>49</volume>
          <year>2010</year>
          <fpage>10149</fpage>
          <lpage>10153</lpage>
        </element-citation>
      </ref>
      <ref id="bib13">
        <element-citation publication-type="journal" id="sref13">
          <person-group person-group-type="author">
            <name>
              <surname>Elliott</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Leske</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Hrdinka</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bagola</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Fiil</surname>
              <given-names>B.K.</given-names>
            </name>
            <name>
              <surname>McLaughlin</surname>
              <given-names>S.H.</given-names>
            </name>
            <name>
              <surname>Wagstaff</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Volkmar</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Christianson</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Kessler</surname>
              <given-names>B.M.</given-names>
            </name>
          </person-group>
          <article-title>SPATA2 links CYLD to LUBAC, activates CYLD, and controls LUBAC signaling</article-title>
          <source>Mol. Cell</source>
          <volume>63</volume>
          <year>2016</year>
          <fpage>990</fpage>
          <lpage>1005</lpage>
          <pub-id pub-id-type="pmid">27591049</pub-id>
        </element-citation>
      </ref>
      <ref id="bib14">
        <element-citation publication-type="journal" id="sref14">
          <person-group person-group-type="author">
            <name>
              <surname>Elliott</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>S.V.</given-names>
            </name>
            <name>
              <surname>Marco-Casanova</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Fiil</surname>
              <given-names>B.K.</given-names>
            </name>
            <name>
              <surname>Keusekotten</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Mailand</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Freund</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Gyrd-Hansen</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Komander</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Molecular basis and regulation of OTULIN-LUBAC interaction</article-title>
          <source>Mol. Cell</source>
          <volume>54</volume>
          <year>2014</year>
          <fpage>335</fpage>
          <lpage>348</lpage>
          <pub-id pub-id-type="pmid">24726323</pub-id>
        </element-citation>
      </ref>
      <ref id="bib15">
        <element-citation publication-type="journal" id="sref15">
          <person-group person-group-type="author">
            <name>
              <surname>Emsley</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Lohkamp</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>W.G.</given-names>
            </name>
            <name>
              <surname>Cowtan</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Features and development of Coot</article-title>
          <source>Acta Crystallogr. D Biol. Crystallogr.</source>
          <volume>66</volume>
          <year>2010</year>
          <fpage>486</fpage>
          <lpage>501</lpage>
          <pub-id pub-id-type="pmid">20383002</pub-id>
        </element-citation>
      </ref>
      <ref id="bib16">
        <element-citation publication-type="journal" id="sref16">
          <person-group person-group-type="author">
            <name>
              <surname>Evans</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Murshudov</surname>
              <given-names>G.N.</given-names>
            </name>
          </person-group>
          <article-title>How good are my data and what is the resolution?</article-title>
          <source>Acta Crystallogr. D Biol. Crystallogr.</source>
          <volume>69</volume>
          <year>2013</year>
          <fpage>1204</fpage>
          <lpage>1214</lpage>
          <pub-id pub-id-type="pmid">23793146</pub-id>
        </element-citation>
      </ref>
      <ref id="bib17">
        <element-citation publication-type="journal" id="sref17">
          <person-group person-group-type="author">
            <name>
              <surname>Faesen</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Luna-Vargas</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>Geurink</surname>
              <given-names>P.P.</given-names>
            </name>
            <name>
              <surname>Clerici</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Merkx</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>van Dijk</surname>
              <given-names>W.J.</given-names>
            </name>
            <name>
              <surname>Hameed</surname>
              <given-names>D.S.</given-names>
            </name>
            <name>
              <surname>El Oualid</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Ovaa</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Sixma</surname>
              <given-names>T.K.</given-names>
            </name>
          </person-group>
          <article-title>The differential modulation of USP activity by internal regulatory domains, interactors and eight ubiquitin chain types</article-title>
          <source>Chem. Biol.</source>
          <volume>18</volume>
          <year>2011</year>
          <fpage>1550</fpage>
          <lpage>1561</lpage>
          <pub-id pub-id-type="pmid">22195557</pub-id>
        </element-citation>
      </ref>
      <ref id="bib18">
        <element-citation publication-type="journal" id="sref18">
          <person-group person-group-type="author">
            <name>
              <surname>Fiil</surname>
              <given-names>B.K.</given-names>
            </name>
            <name>
              <surname>Damgaard</surname>
              <given-names>R.B.</given-names>
            </name>
            <name>
              <surname>Wagner</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Keusekotten</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Fritsch</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bekker-Jensen</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Mailand</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Choudhary</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Komander</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Gyrd-Hansen</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>OTULIN restricts Met1-linked ubiquitination to control innate immune signaling</article-title>
          <source>Mol. Cell</source>
          <volume>50</volume>
          <year>2013</year>
          <fpage>818</fpage>
          <lpage>830</lpage>
          <pub-id pub-id-type="pmid">23806334</pub-id>
        </element-citation>
      </ref>
      <ref id="bib19">
        <element-citation publication-type="journal" id="sref19">
          <person-group person-group-type="author">
            <name>
              <surname>Fiil</surname>
              <given-names>B.K.</given-names>
            </name>
            <name>
              <surname>Gyrd-Hansen</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Met1-linked ubiquitination in immune signalling</article-title>
          <source>FEBS J.</source>
          <volume>281</volume>
          <year>2014</year>
          <fpage>4337</fpage>
          <lpage>4350</lpage>
          <pub-id pub-id-type="pmid">25060092</pub-id>
        </element-citation>
      </ref>
      <ref id="bib20">
        <element-citation publication-type="journal" id="sref20">
          <person-group person-group-type="author">
            <name>
              <surname>Haj-Yahya</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Hemantha</surname>
              <given-names>H.P.</given-names>
            </name>
            <name>
              <surname>Meledin</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Bondalapati</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Seenaiah</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Brik</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Dehydroalanine-based diubiquitin activity probes</article-title>
          <source>Org. Lett.</source>
          <volume>16</volume>
          <year>2014</year>
          <fpage>540</fpage>
          <lpage>543</lpage>
          <pub-id pub-id-type="pmid">24364494</pub-id>
        </element-citation>
      </ref>
      <ref id="bib21">
        <element-citation publication-type="journal" id="sref21">
          <person-group person-group-type="author">
            <name>
              <surname>Hospenthal</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Mevissen</surname>
              <given-names>T.E.</given-names>
            </name>
            <name>
              <surname>Komander</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Deubiquitinase-based analysis of ubiquitin chain architecture using ubiquitin chain restriction (UbiCRest)</article-title>
          <source>Nat. Protoc.</source>
          <volume>10</volume>
          <year>2015</year>
          <fpage>349</fpage>
          <lpage>361</lpage>
          <pub-id pub-id-type="pmid">25633630</pub-id>
        </element-citation>
      </ref>
      <ref id="bib22">
        <element-citation publication-type="journal" id="sref22">
          <person-group person-group-type="author">
            <name>
              <surname>Hrdinka</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Fiil</surname>
              <given-names>B.K.</given-names>
            </name>
            <name>
              <surname>Zucca</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Leske</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Bagola</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Yabal</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Elliott</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Damgaard</surname>
              <given-names>R.B.</given-names>
            </name>
            <name>
              <surname>Komander</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Jost</surname>
              <given-names>P.J.</given-names>
            </name>
          </person-group>
          <article-title>CYLD limits Lys63- and Met1-linked ubiquitin at receptor complexes to regulate innate immune signaling</article-title>
          <source>Cell Rep.</source>
          <volume>14</volume>
          <year>2016</year>
          <fpage>2846</fpage>
          <lpage>2858</lpage>
          <pub-id pub-id-type="pmid">26997266</pub-id>
        </element-citation>
      </ref>
      <ref id="bib23">
        <element-citation publication-type="journal" id="sref23">
          <person-group person-group-type="author">
            <name>
              <surname>Hu</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Yao</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>J.W.</given-names>
            </name>
            <name>
              <surname>Gu</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde</article-title>
          <source>Cell</source>
          <volume>111</volume>
          <year>2002</year>
          <fpage>1041</fpage>
          <lpage>1054</lpage>
          <pub-id pub-id-type="pmid">12507430</pub-id>
        </element-citation>
      </ref>
      <ref id="bib24">
        <element-citation publication-type="journal" id="sref24">
          <person-group person-group-type="author">
            <name>
              <surname>Hu</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Jeffrey</surname>
              <given-names>P.D.</given-names>
            </name>
            <name>
              <surname>Chenova</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Wilkinson</surname>
              <given-names>K.D.</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14</article-title>
          <source>EMBO J.</source>
          <volume>24</volume>
          <year>2005</year>
          <fpage>3747</fpage>
          <lpage>3756</lpage>
          <pub-id pub-id-type="pmid">16211010</pub-id>
        </element-citation>
      </ref>
      <ref id="bib25">
        <element-citation publication-type="journal" id="sref25">
          <person-group person-group-type="author">
            <name>
              <surname>Iwai</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Fujita</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Sasaki</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Linear ubiquitin chains: NF-kappaB signalling, cell death and beyond</article-title>
          <source>Nat. Rev. Mol. Cell Biol.</source>
          <volume>15</volume>
          <year>2014</year>
          <fpage>503</fpage>
          <lpage>508</lpage>
          <pub-id pub-id-type="pmid">25027653</pub-id>
        </element-citation>
      </ref>
      <ref id="bib26">
        <element-citation publication-type="journal" id="sref26">
          <person-group person-group-type="author">
            <name>
              <surname>Keusekotten</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Elliott</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Glockner</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Fiil</surname>
              <given-names>B.K.</given-names>
            </name>
            <name>
              <surname>Damgaard</surname>
              <given-names>R.B.</given-names>
            </name>
            <name>
              <surname>Kulathu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Wauer</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Hospenthal</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Gyrd-Hansen</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Krappmann</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked polyubiquitin</article-title>
          <source>Cell</source>
          <volume>153</volume>
          <year>2013</year>
          <fpage>1312</fpage>
          <lpage>1326</lpage>
          <pub-id pub-id-type="pmid">23746843</pub-id>
        </element-citation>
      </ref>
      <ref id="bib27">
        <element-citation publication-type="journal" id="sref27">
          <person-group person-group-type="author">
            <name>
              <surname>Komander</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Clague</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Urbe</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Breaking the chains: structure and function of the deubiquitinases</article-title>
          <source>Nat. Rev. Mol. Cell Biol.</source>
          <volume>10</volume>
          <year>2009</year>
          <fpage>550</fpage>
          <lpage>563</lpage>
          <pub-id pub-id-type="pmid">19626045</pub-id>
        </element-citation>
      </ref>
      <ref id="bib28">
        <element-citation publication-type="journal" id="sref28">
          <person-group person-group-type="author">
            <name>
              <surname>Komander</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Lord</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Scheel</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Swift</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Hofmann</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Ashworth</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Barford</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module</article-title>
          <source>Mol. Cell</source>
          <volume>29</volume>
          <year>2008</year>
          <fpage>451</fpage>
          <lpage>464</lpage>
          <pub-id pub-id-type="pmid">18313383</pub-id>
        </element-citation>
      </ref>
      <ref id="bib29">
        <element-citation publication-type="journal" id="sref29">
          <person-group person-group-type="author">
            <name>
              <surname>Komander</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Rape</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>The ubiquitin code</article-title>
          <source>Annu. Rev. Biochem.</source>
          <volume>81</volume>
          <year>2012</year>
          <fpage>203</fpage>
          <lpage>229</lpage>
          <pub-id pub-id-type="pmid">22524316</pub-id>
        </element-citation>
      </ref>
      <ref id="bib30">
        <element-citation publication-type="journal" id="sref30">
          <person-group person-group-type="author">
            <name>
              <surname>Komander</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Reyes-Turcu</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Licchesi</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Odenwaelder</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Wilkinson</surname>
              <given-names>K.D.</given-names>
            </name>
            <name>
              <surname>Barford</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains</article-title>
          <source>EMBO Rep.</source>
          <volume>10</volume>
          <year>2009</year>
          <fpage>466</fpage>
          <lpage>473</lpage>
          <pub-id pub-id-type="pmid">19373254</pub-id>
        </element-citation>
      </ref>
      <ref id="bib31">
        <element-citation publication-type="journal" id="sref31">
          <person-group person-group-type="author">
            <name>
              <surname>Kovalevskiy</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Nicholls</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Murshudov</surname>
              <given-names>G.N.</given-names>
            </name>
          </person-group>
          <article-title>Automated refinement of macromolecular structures at low resolution using prior information</article-title>
          <source>Acta Crystallogr. D Struct. Biol.</source>
          <volume>72</volume>
          <year>2016</year>
          <fpage>1149</fpage>
          <lpage>1161</lpage>
          <pub-id pub-id-type="pmid">27710936</pub-id>
        </element-citation>
      </ref>
      <ref id="bib32">
        <element-citation publication-type="journal" id="sref32">
          <person-group person-group-type="author">
            <name>
              <surname>Kupka</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>De Miguel</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Draber</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Martino</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Surinova</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Rittinger</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Walczak</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>SPATA2-mediated binding of CYLD to HOIP enables CYLD recruitment to signaling complexes</article-title>
          <source>Cell Rep.</source>
          <volume>16</volume>
          <year>2016</year>
          <fpage>2271</fpage>
          <lpage>2280</lpage>
          <pub-id pub-id-type="pmid">27545878</pub-id>
        </element-citation>
      </ref>
      <ref id="bib33">
        <element-citation publication-type="journal" id="sref33">
          <person-group person-group-type="author">
            <name>
              <surname>Martinez-Fonts</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Matouschek</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>A rapid and versatile method for generating proteins with defined ubiquitin chains</article-title>
          <source>Biochemistry</source>
          <volume>55</volume>
          <year>2016</year>
          <fpage>1898</fpage>
          <lpage>1908</lpage>
          <pub-id pub-id-type="pmid">26943792</pub-id>
        </element-citation>
      </ref>
      <ref id="bib34">
        <element-citation publication-type="journal" id="sref34">
          <person-group person-group-type="author">
            <name>
              <surname>McCoy</surname>
              <given-names>A.J.</given-names>
            </name>
          </person-group>
          <article-title>Solving structures of protein complexes by molecular replacement with Phaser</article-title>
          <source>Acta Crystallogr. D Biol. Crystallogr.</source>
          <volume>63</volume>
          <year>2007</year>
          <fpage>32</fpage>
          <lpage>41</lpage>
          <pub-id pub-id-type="pmid">17164524</pub-id>
        </element-citation>
      </ref>
      <ref id="bib35">
        <element-citation publication-type="journal" id="sref35">
          <person-group person-group-type="author">
            <name>
              <surname>McGouran</surname>
              <given-names>J.F.</given-names>
            </name>
            <name>
              <surname>Gaertner</surname>
              <given-names>S.R.</given-names>
            </name>
            <name>
              <surname>Altun</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kramer</surname>
              <given-names>H.B.</given-names>
            </name>
            <name>
              <surname>Kessler</surname>
              <given-names>B.M.</given-names>
            </name>
          </person-group>
          <article-title>Deubiquitinating enzyme specificity for ubiquitin chain topology profiled by di-ubiquitin activity probes</article-title>
          <source>Chem. Biol.</source>
          <volume>20</volume>
          <year>2013</year>
          <fpage>1447</fpage>
          <lpage>1455</lpage>
          <pub-id pub-id-type="pmid">24290882</pub-id>
        </element-citation>
      </ref>
      <ref id="bib36">
        <element-citation publication-type="journal" id="sref36">
          <person-group person-group-type="author">
            <name>
              <surname>Mevissen</surname>
              <given-names>T.E.</given-names>
            </name>
            <name>
              <surname>Hospenthal</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Geurink</surname>
              <given-names>P.P.</given-names>
            </name>
            <name>
              <surname>Elliott</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Akutsu</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Arnaudo</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Ekkebus</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Kulathu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Wauer</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>El Oualid</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis</article-title>
          <source>Cell</source>
          <volume>154</volume>
          <year>2013</year>
          <fpage>169</fpage>
          <lpage>184</lpage>
          <pub-id pub-id-type="pmid">23827681</pub-id>
        </element-citation>
      </ref>
      <ref id="bib37">
        <element-citation publication-type="journal" id="sref37">
          <person-group person-group-type="author">
            <name>
              <surname>Mevissen</surname>
              <given-names>T.E.</given-names>
            </name>
            <name>
              <surname>Kulathu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Mulder</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>Geurink</surname>
              <given-names>P.P.</given-names>
            </name>
            <name>
              <surname>Maslen</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Gersch</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Elliott</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Burke</surname>
              <given-names>J.E.</given-names>
            </name>
            <name>
              <surname>van Tol</surname>
              <given-names>B.D.</given-names>
            </name>
            <name>
              <surname>Akutsu</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Molecular basis of Lys11-polyubiquitin specificity in the deubiquitinase Cezanne</article-title>
          <source>Nature</source>
          <volume>538</volume>
          <year>2016</year>
          <fpage>402</fpage>
          <lpage>405</lpage>
          <pub-id pub-id-type="pmid">27732584</pub-id>
        </element-citation>
      </ref>
      <ref id="bib38">
        <element-citation publication-type="journal" id="sref38">
          <person-group person-group-type="author">
            <name>
              <surname>Mulder</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>El Oualid</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>ter Beek</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Ovaa</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>A native chemical ligation handle that enables the synthesis of advanced activity-based probes: diubiquitin as a case study</article-title>
          <source>ChemBioChem</source>
          <volume>15</volume>
          <year>2014</year>
          <fpage>946</fpage>
          <lpage>949</lpage>
          <pub-id pub-id-type="pmid">24623714</pub-id>
        </element-citation>
      </ref>
      <ref id="bib39">
        <element-citation publication-type="journal" id="sref39">
          <person-group person-group-type="author">
            <name>
              <surname>Muller-Rischart</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Pilsl</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Beaudette</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Patra</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hadian</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Funke</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Peis</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Deinlein</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Schweimer</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Kuhn</surname>
              <given-names>P.H.</given-names>
            </name>
          </person-group>
          <article-title>The E3 ligase parkin maintains mitochondrial integrity by increasing linear ubiquitination of NEMO</article-title>
          <source>Mol. Cell</source>
          <volume>49</volume>
          <year>2013</year>
          <fpage>908</fpage>
          <lpage>921</lpage>
          <pub-id pub-id-type="pmid">23453807</pub-id>
        </element-citation>
      </ref>
      <ref id="bib40">
        <element-citation publication-type="journal" id="sref40">
          <person-group person-group-type="author">
            <name>
              <surname>Murshudov</surname>
              <given-names>G.N.</given-names>
            </name>
            <name>
              <surname>Skubak</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Lebedev</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Pannu</surname>
              <given-names>N.S.</given-names>
            </name>
            <name>
              <surname>Steiner</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Nicholls</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Winn</surname>
              <given-names>M.D.</given-names>
            </name>
            <name>
              <surname>Long</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Vagin</surname>
              <given-names>A.A.</given-names>
            </name>
          </person-group>
          <article-title>REFMAC5 for the refinement of macromolecular crystal structures</article-title>
          <source>Acta Crystallogr. D Biol. Crystallogr.</source>
          <volume>67</volume>
          <year>2011</year>
          <fpage>355</fpage>
          <lpage>367</lpage>
          <pub-id pub-id-type="pmid">21460454</pub-id>
        </element-citation>
      </ref>
      <ref id="bib41">
        <element-citation publication-type="journal" id="sref41">
          <person-group person-group-type="author">
            <name>
              <surname>Renatus</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Parrado</surname>
              <given-names>S.G.</given-names>
            </name>
            <name>
              <surname>D'Arcy</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Eidhoff</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Gerhartz</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Hassiepen</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Pierrat</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Riedl</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Vinzenz</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Worpenberg</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Structural basis of ubiquitin recognition by the deubiquitinating protease USP2</article-title>
          <source>Structure</source>
          <volume>14</volume>
          <year>2006</year>
          <fpage>1293</fpage>
          <lpage>1302</lpage>
          <pub-id pub-id-type="pmid">16905103</pub-id>
        </element-citation>
      </ref>
      <ref id="bib42">
        <element-citation publication-type="journal" id="sref42">
          <person-group person-group-type="author">
            <name>
              <surname>Reyes-Turcu</surname>
              <given-names>F.E.</given-names>
            </name>
            <name>
              <surname>Horton</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Mullally</surname>
              <given-names>J.E.</given-names>
            </name>
            <name>
              <surname>Heroux</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Wilkinson</surname>
              <given-names>K.D.</given-names>
            </name>
          </person-group>
          <article-title>The ubiquitin binding domain ZnF UBP recognizes the C-terminal diglycine motif of unanchored ubiquitin</article-title>
          <source>Cell</source>
          <volume>124</volume>
          <year>2006</year>
          <fpage>1197</fpage>
          <lpage>1208</lpage>
          <pub-id pub-id-type="pmid">16564012</pub-id>
        </element-citation>
      </ref>
      <ref id="bib43">
        <element-citation publication-type="journal" id="sref43">
          <person-group person-group-type="author">
            <name>
              <surname>Reyes-Turcu</surname>
              <given-names>F.E.</given-names>
            </name>
            <name>
              <surname>Shanks</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Komander</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Wilkinson</surname>
              <given-names>K.D.</given-names>
            </name>
          </person-group>
          <article-title>Recognition of polyubiquitin isoforms by the multiple ubiquitin binding modules of isopeptidase T</article-title>
          <source>J.Â Biol. Chem.</source>
          <volume>283</volume>
          <year>2008</year>
          <fpage>19581</fpage>
          <lpage>19592</lpage>
          <pub-id pub-id-type="pmid">18482987</pub-id>
        </element-citation>
      </ref>
      <ref id="bib44">
        <element-citation publication-type="journal" id="sref44">
          <person-group person-group-type="author">
            <name>
              <surname>Rivkin</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Ceccarelli</surname>
              <given-names>D.F.</given-names>
            </name>
            <name>
              <surname>Juang</surname>
              <given-names>Y.C.</given-names>
            </name>
            <name>
              <surname>MacLean</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Srikumar</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Dunham</surname>
              <given-names>W.H.</given-names>
            </name>
            <name>
              <surname>Fukumura</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>The linear ubiquitin-specific deubiquitinase gumby regulates angiogenesis</article-title>
          <source>Nature</source>
          <volume>498</volume>
          <year>2013</year>
          <fpage>318</fpage>
          <lpage>324</lpage>
          <pub-id pub-id-type="pmid">23708998</pub-id>
        </element-citation>
      </ref>
      <ref id="bib45">
        <element-citation publication-type="journal" id="sref45">
          <person-group person-group-type="author">
            <name>
              <surname>Sasaki</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Iwai</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Roles of linear ubiquitinylation, a crucial regulator of NF-kappaB and cell death, in the immune system</article-title>
          <source>Immunol. Rev.</source>
          <volume>266</volume>
          <year>2015</year>
          <fpage>175</fpage>
          <lpage>189</lpage>
          <pub-id pub-id-type="pmid">26085215</pub-id>
        </element-citation>
      </ref>
      <ref id="bib46">
        <element-citation publication-type="journal" id="sref46">
          <person-group person-group-type="author">
            <name>
              <surname>Sato</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Goto</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Shibata</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Kubota</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Yamagata</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Goto-Ito</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kubota</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Takekawa</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Tokunaga</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Structures of CYLD USP with Met1- or Lys63-linked diubiquitin reveal mechanisms for dual specificity</article-title>
          <source>Nat. Struct. Mol. Biol.</source>
          <volume>22</volume>
          <year>2015</year>
          <fpage>222</fpage>
          <lpage>229</lpage>
          <pub-id pub-id-type="pmid">25686088</pub-id>
        </element-citation>
      </ref>
      <ref id="bib47">
        <element-citation publication-type="journal" id="sref47">
          <person-group person-group-type="author">
            <name>
              <surname>Schaeffer</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Akutsu</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Olma</surname>
              <given-names>M.H.</given-names>
            </name>
            <name>
              <surname>Gomes</surname>
              <given-names>L.C.</given-names>
            </name>
            <name>
              <surname>Kawasaki</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Dikic</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Binding of OTULIN to the PUB domain of HOIP controls NF-kappaB signaling</article-title>
          <source>Mol. Cell</source>
          <volume>54</volume>
          <year>2014</year>
          <fpage>349</fpage>
          <lpage>361</lpage>
          <pub-id pub-id-type="pmid">24726327</pub-id>
        </element-citation>
      </ref>
      <ref id="bib48">
        <element-citation publication-type="journal" id="sref48">
          <person-group person-group-type="author">
            <name>
              <surname>Scharschmidt</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Wegener</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Heissmeyer</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Krappmann</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Degradation of Bcl10 induced by T-cell activation negatively regulates NF-kappa B signaling</article-title>
          <source>Mol. Cell. Biol.</source>
          <volume>24</volume>
          <year>2004</year>
          <fpage>3860</fpage>
          <lpage>3873</lpage>
          <pub-id pub-id-type="pmid">15082780</pub-id>
        </element-citation>
      </ref>
      <ref id="bib49">
        <element-citation publication-type="journal" id="sref49">
          <person-group person-group-type="author">
            <name>
              <surname>Schimmack</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Schorpp</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kutzner</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Gehring</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Brenke</surname>
              <given-names>J.K.</given-names>
            </name>
            <name>
              <surname>Hadian</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Krappmann</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>YOD1/TRAF6 association balances p62-dependent IL-1 signaling to NF-kappaB</article-title>
          <source>eLife</source>
          <volume>6</volume>
          <year>2017</year>
        </element-citation>
      </ref>
      <ref id="bib50">
        <element-citation publication-type="journal" id="sref50">
          <person-group person-group-type="author">
            <name>
              <surname>Schlicher</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Wissler</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Preiss</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Brauns-Schubert</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Jakob</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Dumit</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Borner</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Dengjel</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Maurer</surname>
              <given-names>U.</given-names>
            </name>
          </person-group>
          <article-title>SPATA2 promotes CYLD activity and regulates TNF-induced NF-kappaB signaling and cell death</article-title>
          <source>EMBO Rep.</source>
          <volume>17</volume>
          <year>2016</year>
          <fpage>1485</fpage>
          <lpage>1497</lpage>
          <pub-id pub-id-type="pmid">27458237</pub-id>
        </element-citation>
      </ref>
      <ref id="bib51">
        <element-citation publication-type="journal" id="sref51">
          <person-group person-group-type="author">
            <name>
              <surname>Setsuie</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Sakurai</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sakaguchi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Wada</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Ubiquitin dimers control the hydrolase activity of UCH-L3</article-title>
          <source>Neurochem. Int.</source>
          <volume>54</volume>
          <year>2009</year>
          <fpage>314</fpage>
          <lpage>321</lpage>
          <pub-id pub-id-type="pmid">19154770</pub-id>
        </element-citation>
      </ref>
      <ref id="bib52">
        <element-citation publication-type="journal" id="sref52">
          <person-group person-group-type="author">
            <name>
              <surname>Strachan</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Roach</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Sokratous</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Tooth</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Long</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Garner</surname>
              <given-names>T.P.</given-names>
            </name>
            <name>
              <surname>Searle</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Oldham</surname>
              <given-names>N.J.</given-names>
            </name>
            <name>
              <surname>Layfield</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Insights into the molecular composition of endogenous unanchored polyubiquitin chains</article-title>
          <source>J.Â Proteome Res.</source>
          <volume>11</volume>
          <year>2012</year>
          <fpage>1969</fpage>
          <lpage>1980</lpage>
          <pub-id pub-id-type="pmid">22268864</pub-id>
        </element-citation>
      </ref>
      <ref id="bib53">
        <element-citation publication-type="journal" id="sref53">
          <person-group person-group-type="author">
            <name>
              <surname>Virdee</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ye</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>D.P.</given-names>
            </name>
            <name>
              <surname>Komander</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Chin</surname>
              <given-names>J.W.</given-names>
            </name>
          </person-group>
          <article-title>Engineered diubiquitin synthesis reveals Lys29-isopeptide specificity of an OTU deubiquitinase</article-title>
          <source>Nat. Chem. Biol.</source>
          <volume>6</volume>
          <year>2010</year>
          <fpage>750</fpage>
          <lpage>757</lpage>
          <pub-id pub-id-type="pmid">20802491</pub-id>
        </element-citation>
      </ref>
      <ref id="bib54">
        <element-citation publication-type="journal" id="sref54">
          <person-group person-group-type="author">
            <name>
              <surname>Vizcaino</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Csordas</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>del-Toro</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Dianes</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Griss</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lavidas</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Mayer</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Perez-Riverol</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Reisinger</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Ternent</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>2016 update of the PRIDE database and its related tools</article-title>
          <source>Nucleic Acids Res.</source>
          <volume>44</volume>
          <year>2016</year>
          <fpage>D447</fpage>
          <lpage>D456</lpage>
          <pub-id pub-id-type="pmid">26527722</pub-id>
        </element-citation>
      </ref>
      <ref id="bib55">
        <element-citation publication-type="journal" id="sref55">
          <person-group person-group-type="author">
            <name>
              <surname>Wagner</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Satpathy</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Beli</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Choudhary</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>SPATA2 links CYLD to the TNF-alpha receptor signaling complex and modulates the receptor signaling outcomes</article-title>
          <source>EMBO J.</source>
          <volume>35</volume>
          <year>2016</year>
          <fpage>1868</fpage>
          <lpage>1884</lpage>
          <pub-id pub-id-type="pmid">27307491</pub-id>
        </element-citation>
      </ref>
      <ref id="bib56">
        <element-citation publication-type="journal" id="sref56">
          <person-group person-group-type="author">
            <name>
              <surname>Wessel</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Flugge</surname>
              <given-names>U.I.</given-names>
            </name>
          </person-group>
          <article-title>A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids</article-title>
          <source>Anal. Biochem.</source>
          <volume>138</volume>
          <year>1984</year>
          <fpage>141</fpage>
          <lpage>143</lpage>
          <pub-id pub-id-type="pmid">6731838</pub-id>
        </element-citation>
      </ref>
      <ref id="bib57">
        <element-citation publication-type="journal" id="sref57">
          <person-group person-group-type="author">
            <name>
              <surname>Winter</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Lobley</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Prince</surname>
              <given-names>S.M.</given-names>
            </name>
          </person-group>
          <article-title>Decision making in xia2</article-title>
          <source>Acta Crystallogr. D Biol. Crystallogr.</source>
          <volume>69</volume>
          <year>2013</year>
          <fpage>1260</fpage>
          <lpage>1273</lpage>
          <pub-id pub-id-type="pmid">23793152</pub-id>
        </element-citation>
      </ref>
      <ref id="bib58">
        <element-citation publication-type="journal" id="sref58">
          <person-group person-group-type="author">
            <name>
              <surname>Ye</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Akutsu</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Reyes-Turcu</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Enchev</surname>
              <given-names>R.I.</given-names>
            </name>
            <name>
              <surname>Wilkinson</surname>
              <given-names>K.D.</given-names>
            </name>
            <name>
              <surname>Komander</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Polyubiquitin binding and cross-reactivity in the USP domain deubiquitinase USP21</article-title>
          <source>EMBO Rep.</source>
          <volume>12</volume>
          <year>2011</year>
          <fpage>350</fpage>
          <lpage>357</lpage>
          <pub-id pub-id-type="pmid">21399617</pub-id>
        </element-citation>
      </ref>
      <ref id="bib59">
        <element-citation publication-type="journal" id="sref59">
          <person-group person-group-type="author">
            <name>
              <surname>Zhou</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Demirkaya</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Deuitch</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Stone</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Tsai</surname>
              <given-names>W.L.</given-names>
            </name>
            <name>
              <surname>Kuehn</surname>
              <given-names>H.S.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>Y.H.</given-names>
            </name>
          </person-group>
          <article-title>Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <volume>113</volume>
          <year>2016</year>
          <fpage>10127</fpage>
          <lpage>10132</lpage>
          <pub-id pub-id-type="pmid">27559085</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <sec id="appsec2" sec-type="supplementary-material">
      <title>Supplemental Information</title>
      <p>
        <supplementary-material content-type="local-data" id="mmc1">
          <caption>
            <title>Document S1. Figures S1âS5 and Tables S1 and S2</title>
          </caption>
          <media xlink:href="mmc1.pdf"/>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="mmc2">
          <caption>
            <title>Document S2. Article plus Supplemental Information</title>
          </caption>
          <media xlink:href="mmc2.pdf"/>
        </supplementary-material>
      </p>
    </sec>
    <ack id="ack0010">
      <title>Acknowledgments</title>
      <p>We thank Kamyar Hadian, Elisabeth Kremmer, Vishva Dixit, and Titia Sixma for providing reagents. We thank beamline staff at DLS I04 for their assistance. Access to DLS was supported in part by the <funding-source id="gs1">EU FP7</funding-source> infrastructure grant BIOSTRUCT-X (contract no. 283570). Work in the D.Ko. lab is supported by the <funding-source id="gs2">Medical Research Council</funding-source> (U105192732), the <funding-source id="gs3">European Research Council</funding-source> (309756), and the <funding-source id="gs4">Lister Institute of Preventive Medicine</funding-source>. F.E.O. declares competing financial interests as co-founder and shareholder of UbiQ Bio BV. D.Ko. and B.M.K. are part of the DUB Alliance that includes Cancer Research Technology and FORMA Therapeutics.</p>
    </ack>
    <fn-group>
      <fn id="appsec1" fn-type="supplementary-material">
        <p>Supplemental Information includes five figures and two tables and can be found with this article online at <ext-link ext-link-type="doi" xlink:href="10.1016/j.chembiol.2017.08.006" id="intref0170">http://dx.doi.org/10.1016/j.chembiol.2017.08.006</ext-link>.</p>
      </fn>
    </fn-group>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>